Document:

<PAGE>

                                                                   EXHIBIT 10.6

                            STOCK PURCHASE AGREEMENT

     THIS AGREEMENT (this "Agreement") is entered into as of the 21st day of
July, 1997, by and between GENVEC, INC., a Delaware corporation, with its
principal place of business at 12111 Parklawn Drive, Rockville, Maryland 20852
(the "Company"), and WARNER-LAMBERT COMPANY, a Delaware corporation, with its
principal place of business at 201 Tabor Road, Morris Plains, New Jersey 07950
(the "Investor"), with reference to the following recitals:

     WHEREAS, the Company and the Investor have entered into a Research,
Development and Collaboration Agreement, dated as of the date hereof (the
"Collaboration Agreement"), pursuant to which the Company and the Investor have
agreed to enter into a collaborative effort, as defined in the Collaboration
Agreement (the "Collaboration"), and have established a framework for their
collaboration, as described in the Collaboration Agreement; and

     WHEREAS, the Investor agrees to purchase certain shares of the capital
stock of the Company on and pursuant to the terms hereinafter set forth.

     NOW, THEREFORE, in consideration of the mutual agreements, undertakings and
covenants set forth in this Agreement and in the Collaboration Agreement, and
for other good and valuable consideration, the receipt, sufficiency and adequacy
of which are hereby acknowledged, the parties, intending to be legally bound,
hereby agree as follows:

     1.   DEFINITIONS.  For purposes of this Agreement the following terms shall
have the meanings ascribed to them in this Section 1 except as otherwise
expressly indicated or limited by the context in which they appear in this
Agreement.  All terms defined in Section 1 or in the Preamble to this Agreement
in the singular form shall have the same meaning when used in the plural form
and vice versa.

          (a) "Affiliate" shall mean a person or entity that directly, or
indirectly through one or more intermediaries, controls or is controlled by, or
is under common control with, the person or entity specified.

          (b) "Aggregate Purchase Price" shall mean, in each instance of a
Tranche Event (as defined below), the cash consideration as specified by the
Company in a Sale Notice (as defined below) or Amended Sale Notice (as defined
below) to be paid by the Investor for the Securities (as defined below)
specified therein; provided however, the amount of such cash consideration shall
not exceed Two Million Dollars ($2,000,000) for the Tranche Event described in
Section l(mm)(1), Three Million Dollars ($3,000,000) for the Tranche Event
described in Section l(mm)(2), Five Million Dollars ($5,000,000) for the Tranche
Event described in Section I (mm)(3), Five Million Dollars ($5,000,000) for the
Tranche Event described in Section 1(mm)(4), Five Million Dollars ($5,000,000)
for the Tranche Event described in Section 1(mm)(5), and Five Million Dollars
($5,000,000) for the Tranche Event described in Section l(mm)(6).

          (c) "Amended Sale Notice" shall mean the written notice given under
certain circumstances by the Company to the Investor in accordance with Section
2(b)(i)(C) of this Agreement that (i) indicates that the Investor must acquire
Securities in accordance with this Agreement and (ii) provides the information
set forth in Section 2(b)(i)(C) hereof, as appropriate.

          (d) "Bylaws" shall mean the Company's Amended and Restated By-Laws as
set forth in Exhibit B hereto, as amended from time to time.

          (e) "Business Day" shall mean each Monday, Tuesday, Wednesday,
Thursday and Friday which is not a day when the banking institutions in Maryland
are authorized or obligated by law or proclamation to close or be closed.

          (f) "CAD" shall have the meaning ascribed thereto in the Collaboration
Agreement.

          (g) "CAD Milestone I" shall mean with respect to a Collaboration
Product (as defined below) for the treatment of CAD, the enrollment of the first
human patient in a clinical trial.

          (h) "CAD Milestone II" shall mean with respect to a Collaboration
Product (as defined below) for the treatment of CAD the earliest of:  (x) the
first completion, as determined by the Executive Committee (as defined below),
of the initial Phase I (as defined in the Collaboration Agreement) clinical
trial, (y) the treatment of all patients in a Phase I (as defined in the
Collaboration Agreement) clinical trial per the initial clinical protocol or
thirty (30) days after the administration of a Collaboration Product to three
(3) patients at a dose of ten to the ninth power (10/9/) plaque forming units
(or equivalent), or (z) the enrollment of the first patient in the initial Phase
II (as defined in the Collaboration Agreement) or Phase III (as defined in the
Collaboration Agreement) or Pivotal (as defined in the Collaboration Agreement)
clinical trial (whichever is earliest) which (i) is intended to include thirty
(30) or more patients, or (ii) is approved by the Drug Development Committee (as
defined in the Collaboration Agreement).

          (i) "Charter" shall mean the Company's Restated Certificate of
Incorporation as set forth in Exhibit A hereto, as amended from time to time.

          (j) "Class A Preferred Stock" shall mean the Company's Class A
Convertible Preferred Stock, par value $.01 per share.

          (k) "Class B Preferred Stock" shall mean the Company's Class B
Convertible Preferred Stock, par value $.01 per share.

          (l) "Class C Preferred Stock" shall mean the Company's Class C
Convertible Preferred Stock, par value $.01 per share, and the shares of Common
Stock (as defined below) that have been issued upon conversion of the Class C
Preferred Stock.

                                      -2-

<PAGE>

          (m) "Class D Preferred Stock" shall mean the Company's Class D
Convertible Preferred Stock, par value $.01 per share.

          (n) "Collaboration Product" shall have the meaning ascribed thereto in
the Collaboration Agreement.

          (o) "Commission" shall mean the United States Securities and Exchange
Commission.

          (p) "Common Stock" shall mean the Company's common stock, par value
$.01 per share, or any common stock issued by the Company in exchange for such
Common Stock.

          (q) "Executive Committee" shall have the meaning ascribed thereto in
the Collaboration Agreement.

          (r) "Fair Market Value" shall mean, if the Company has sold shares of
Common Stock in an IPO (as defined below), the average of the daily closing bid
and ask prices for a share of the Common Stock for the Trading Period (as
defined below) on the principal national securities exchange or quotation system
on which the Common Stock is listed or quoted. "Fair Market Value" shall mean,
if the closing bid and ask prices of a share of Common Stock are not so listed
or quoted or if the Company has not sold shares of Common Stock in an IPO, the
fair market value of a share of Common Stock or Preferred Stock (as defined
below), respectively, as reasonably determined by the Company's board of
directors on a date no more than fifteen (15) Business Days prior to the date
that the applicable Sale Notice or Amended Sale Notice is to be sent to the
Investor.  The Company will provide to the Investor notice of the Fair Market
Value no less than ten (10) Business Days prior to the date the applicable Sale
Notice is to be sent to the Investor.  If the Investor disagrees with the
board's determination of the Fair Market Value, it must provide to the Company
notice within five (5) Business Days of receiving the Company's notice of the
Fair Market Value that the Investor disagrees with the board's determination of
the Fair Market Value in which case the Fair Market Value shall be determined by
an appraiser that is selected and paid for by the Company and is reasonably
acceptable to the Investor.  The Fair Market Value will then be the amount
determined by the appraiser as of the same date as of which the Company's board
of directors determined the Fair Market Value with which the Investor disagreed.

          (s) "GAAP" shall mean generally accepted accounting principles in the
United States.

          (t) "Investment Company Act" shall mean the Investment Company Act of
1940, as amended.

                                      -3-

<PAGE>

          (u) "IPO" shall mean an initial underwritten public offering of shares
of Common Stock through the registration of the shares on a registration
statement filed under the Securities Act (as defined below).

          (v) "Lock-up Period" shall mean each of:  (i) the period commencing on
the date of this Agreement and ending two (2) years after the Company sells
shares of Common Stock in an IPO; (ii) the period commencing ninety (90) days
prior to the anticipated date of the occurrence of any Tranche Event and ending
on the day the Investor receives the Sale Notice regarding such Tranche Event
from the Company, and (iii) with respect to Securities sold to the Investor in
connection with each Tranche Event occurring after the Company sells shares of
Common Stock in an IPO, the period commencing on the date the Investor becomes
the holder of record of the Securities purchased in connection with such Tranche
Event and ending on the latter of the lock-up period in this Section 1(v)(i) or
eighteen (18) months after the date the Investor becomes the holder of record of
such Securities determined on a Tranche Event-by-Tranche Event basis.

          (w) "Manufacturing Milestone" shall mean the reproducible
demonstration, as shown by the preparation of three (3) consecutive lots of the
first Collaboration Product, of a process for the production and purification of
Bulk Product (as defined in the Collaboration Agreement) at the scale and in a
GMP facility agreed to by the Executive Committee that is usable for the conduct
of a Pivotal (as defined in the Collaboration Agreement) study of such
Collaboration Product.

          (x) "Original Registration Stock" shall mean the shares of the Class A
Preferred Stock and the Class B Preferred Stock, the shares of Common Stock that
have been issued upon conversion of the Class A Preferred Stock and the Class B
Preferred Stock, and any shares of Common Stock or other securities issued in
respect of any such securities upon any stock split, stock dividend,
recapitalization, merger, consolidation or similar event.

          (y) "Other Shares" shall mean the issued and outstanding shares of
Common Stock proposed to be included in the Piggyback Registration Statement (as
defined below) and held by holders of shares other than the Investor and holders
of any of the Original Registration Stock, the Class C Preferred Stock, and the
Warrant Shares (as defined below).

          (z) "PVD" shall have the meaning ascribed thereto in the Collaboration
Agreement.

          (aa)  "PVD Milestone" shall mean with respect to a Collaboration
Product for the treatment of PVD, the earlier of (i) the first completion, as
determined by the Executive Committee, of the initial Phase I (as defined in the
Collaboration Agreement) clinical trial which comprises less than twelve (12)
patients, or (ii) the administration of a Collaboration Product to the first
twelve (12) patients in any clinical trial.

          (bb)  "Piggyback Registration Statement" shall have the meaning
ascribed thereto in Section 8(a) herein.

                                      -4-

<PAGE>

          (cc)  "Preferred Stock" shall mean shares of any of one or more series
of convertible preferred stock which the Company's board of directors shall
authorize for issuance pursuant to the terms of this Agreement and which the
Investor must purchase pursuant to this Agreement.  Each share of Preferred
Stock shall have the designations, limitations and rights specified in
subsections B(l), (2)(a) and (4) of Article Ninth of the Charter.  Each share of
Preferred Stock (i) shall be entitled to liquidation rights pursuant to the
provisions of B(3) of Article Ninth of the Charter except that the Liquidation
Preference (as defined in the Charter) of the Preferred Stock shall be the same
as the purchase price and (ii) shall be convertible at the option of the
Investor pursuant to the provisions of subsection B(5)(b) of Article Ninth of
the Charter into shares of the Common Stock of the Company at a rate of one
share of Common Stock for each share of Preferred Stock, subject to adjustment
pursuant to the provisions of subsection B(5)(d)(iv) and (v) of Article Ninth of
the Charter, provided, however, that such conversion shall be mandatory upon an
IPO pursuant to the provisions of subsection (B)(6) of Article Ninth of the
Charter.

          (dd)  "Restriction Period" shall mean the period commencing on the
date the Company sells Common Stock in an IPO and ending one year after the
Company receives notice from the Investor or otherwise becomes aware of the
occurrence of (i) all of the Tranche Events or (ii) the Tranche Event that is
the last of the Tranche Events that is reasonably likely to occur, as mutually
agreed to by the Investor and the Company.

          (ee)  "Sale Notice" shall mean the written notice given by the Company
to the Investor that (i) indicates that the Investor must acquire Securities in
accordance with this Agreement and (ii) provides the information set forth in
Section 2(a) or 2(b) hereof, as appropriate.

          (ff)  "Security" shall mean a share of Common Stock or Preferred Stock
issued by the Company to the Investor pursuant to this Agreement.

          (gg)  "Securities Act" shall mean the Securities Act of 1933, as
amended.

          (hh)  "Selling Stockholders" shall mean the holders of shares of
Common Stock which seek to have their shares registered for sale on a
registration statement.

          (ii)  "Subsidiary" shall mean any corporation the majority of the
voting capital stock of which is owned directly or indirectly beneficially or of
record by the Company or the Investor, as applicable.

          (jj)  "Term of the Research Program" shall have the meaning ascribed
thereto in the Collaboration Agreement.

          (kk)  "Third Indication Milestone" shall mean the first indication
other than PVD or CAD for which a Collaboration Product achieves either (i) the
first completion, as determined by the Executive Committee, of the initial Phase
I (as defined in the Collaboration Agreement) clinical trial

                                      -5-

<PAGE>

which comprises less than twelve (12) patients or (ii) the administration of a
Collaboration Product to the first twelve (12) patients in any clinical trial.

          (ll)  "Trading Period" shall mean the twenty (20) consecutive trading
days ending one Business Day prior to the Business Day on which the Investor
must pay the Aggregate Purchase Price for the shares of Common Stock being sold.

          (mm)  "Tranche Event" shall mean each of the events specified below.
The occurrence of each Tranche Event, independently and without regard to
whether any one of the other Tranche Events has or has not occurred, entitles
the Company to sell Securities to the Investor for the Aggregate Purchase Price,
provided that, prior to such occurrence, Pre-Clinical Activities (as defined in
the Collaboration Agreement) or Development (as defined in the Collaboration
Agreement) with respect to all Development Candidates (as defined in the
Collaboration Agreement) (and corresponding Collaboration Products) for the
related clinical indication set forth in subparagraphs (1), (2) and (4) below
have not been terminated under the Collaboration Agreement:

                (1)  CAD Milestone I;

                (2)  CAD Milestone II;

                (3)  An IPO;

                (4)  PVD Milestone;

                (5) Third Indication Milestone; and

                (6)  Manufacturing Milestone.

          (nn)  "Transfer" or "Transferred" shall mean to sell, assign, pledge,
hypothecate, encumber or in any other manner transfer or dispose of or to have
sold, assigned, pledged, hypothecated, encumbered or in any other manner
transferred or disposed of

          (oo)  "Transferee" shall mean a person or entity to which this
Agreement or the Securities are Transferred.

          (pp)  "Warrant Shares" shall mean any shares of Common Stock acquired
by Scios Inc. pursuant to the Warrant Agreement entered into by the Company with
Scios Inc. as of May 31, 1996

     2.   PURCHASE OF STOCK.  As set forth below, the Investor agrees to
purchase Securities issued by the Company for an aggregate amount not to exceed
Twenty-Five Million Dollars ($25,000,000) subject to the terms and conditions
contained in this Agreement.  Such purchase will be made in up to six (6)
separate transactions with each such transaction occurring simultaneously with
or after the occurrence of a Tranche Event and after receipt by the Investor of
a Sale Notice for

                                      -6-

<PAGE>

each such purchase. The Investor agrees to purchase shares of Common Stock at
the time the Company sells shares of Common Stock in an IPO and, thereafter,
after the occurrence of each of the other Tranche Events. Prior to the sale of
shares of Common Stock in an IPO, the Investor agrees to purchase shares of
Preferred Stock after each Tranche Event. The Company's right to sell Securities
and the Investor's obligation to purchase Securities are subject to the right of
the Investor to refuse to acquire any portion of the Securities specified in the
Sale Notice, if, at the time of such acquisition, and after taking into account
the conversion into shares of Common Stock of any and all outstanding shares of
the Company's preferred stock and the shares of Preferred Stock specified in the
Sale Notice, the purchase of such portion of Securities would result in the
Investor owning twenty percent (20%) or more of the outstanding shares of Common
Stock and the shares of Common Stock into which the Company's outstanding shares
of preferred stock and the shares of Preferred Stock specified in the Sale
Notice are convertible.

          (a) PURCHASE OF COMMON STOCK UPON AN IPO.  If the Company intends to
sell shares of Common Stock to the Investor at the time of the sale of shares of
Common Stock in an IPO, at least thirty (30) days before the effectiveness of
the registration statement filed under the Securities Act in connection with the
IPO, the Company will provide a Sale Notice to the Investor to inform the
Investor that it must purchase shares of Common Stock in accordance with this
Agreement.

              (i)     The Sale Notice will advise the Investor of the Aggregate
Purchase Price and the estimated range of prices at which the shares of Common
Stock may be sold in the IPO. The Investor agrees to pay a purchase price for
each share of Common Stock equal to one-hundred twenty-five percent (125%) of
the price at which a share of Common Stock is sold to the public in the IPO. The
number of shares of Common Stock that the Investor will purchase will equal the
Aggregate Purchase Price divided by the product of 1.25 times the price at which
a share of Common Stock is sold to the public in the IPO, rounded down, if
necessary, to the next whole number of shares. The Aggregate Purchase Price
shall be reduced by the purchase price of the fractional share not issued.

              (ii)    The purchase and sale of the shares of Common Stock shall
take place simultaneously with the closing of the IPO or on a Business Day no
more than one full Business Day after the closing of the IPO.  The Investor
shall deliver the payment for the shares of Common Stock by a wire transfer of
immediately available funds or by a certified bank check payable to the order of
the Company in the amount of the Aggregate Purchase Price.  Upon receipt of such
payment by the Company, the Investor will be deemed to be the holder of record
of the shares of Common Stock and the Company will promptly execute and provide
to the Investor a certificate or certificates evidencing issuance to the
Investor of the appropriate number of fully-paid and non-assessable shares of
Common Stock purchased.  The Company and the Investor shall comply with the
conditions to the sale set forth in Sections 9 and 10 hereof.

              (iii)   The Company agrees to advise the Investor periodically
as to the expected timing of the closing of the IPO. If shares of Common Stock
are not sold in the IPO with

                                      -7-

<PAGE>

respect to which the Sale Notice is given, the Company shall continue to have
the right to provide a Sale Notice and sell shares of the Common Stock pursuant
to this Section 2(a) in connection with any future IPO.

          (b) PURCHASE OF SECURITIES UPON THE OCCURRENCE OF A TRANCHE EVENT
OTHER THAN AN IPO.  If the Company intends to sell Securities after the
occurrence of a Tranche Event other than an IPO, the Company will provide a Sale
Notice to the Investor to inform the Investor that it must acquire the
Securities in accordance with this Agreement.  The Sale Notice will advise the
Investor to purchase shares of either Common Stock or Preferred Stock as set
forth below.

              (i)  PURCHASE OF SECURITIES BEFORE AN IPO.

                   (A) The Sale Notice will be sent to the Investor no more
than ninety (90) days after the Company receives notice from the Investor or
otherwise becomes aware of the occurrence of a Tranche Event that occurs before
the sale of shares of Common Stock in an IPO, or such longer period of time to
enable the Company to obtain an appraisal of the Fair Market Value of the
Preferred Stock, if required. The Sale Notice will advise the Investor of the
number of shares of Preferred Stock that the Company has determined to sell to
the Investor, the Fair Market Value of each such share of Preferred Stock, the
purchase price for each such share of Preferred Stock and the Aggregate Purchase
Price. The Investor agrees to pay a purchase price for each share of Preferred
Stock equal to one-hundred twenty-five percent (125%) of the Fair Market Value
of a share of such Preferred Stock. Within thirty (30) days of the Investor's
receipt of the Sale Notice, the Investor shall deliver the payment for such
shares of Preferred Stock by a wire transfer of immediately available funds or
by a certified bank check payable to the order of the Company in the amount of
the Aggregate Purchase Price. Upon receipt of such payment by the Company on a
Business Day, the Investor will be deemed to be the holder of record of such
shares of Preferred Stock and the Company will promptly execute and provide to
the Investor a certificate or certificates evidencing issuance to the Investor
of the appropriate number of fully-paid and non-assessable shares of such
Preferred Stock. The Company and the Investor shall comply with the conditions
to the sale set forth in Sections 9 and 10 hereof.

                   (B) Notwithstanding paragraph (A) of this Section 2(b)(i),
if the Company sends a Sale Notice in connection with a Tranche Event other than
an IPO after it has filed a registration statement for an IPO which is being
reviewed by the Commission, the Sale Notice shall advise the Investor that the
Investor will purchase shares of Common Stock and will specify the Aggregate
Purchase Price and the estimated range of prices at which such shares of Common
Stock may be sold in the IPO. The Investor agrees to pay a purchase price for
each share of Common Stock equal to one-hundred twenty-five percent (125%) of
the price at which a share of Common Stock is sold to the public in the IPO. The
number of shares of Common Stock that the Investor will purchase will equal the
Aggregate Purchase Price divided by the product of 1.25 times the price at which
a share of Common Stock is sold to the public in the IPO, rounded down, if
necessary, to the next whole number of shares. The Aggregate Purchase Price
shall be reduced by the purchase price of the fractional share not issued. The
purchase and sale of the shares of Common Stock shall take

                                      -8-

<PAGE>

place simultaneously with the closing of the IPO or on a Business Day no more
than one full Business Day after the closing of the IPO. The Investor shall
deliver the payment for the shares of Common Stock by a wire transfer of
immediately available funds or by a certified bank check payable to the order of
the Company in the amount of the Aggregate Purchase Price. Upon receipt of such
payment by the Company, the Investor will be deemed to be the holder of record
of the shares of Common Stock and the Company will promptly execute and provide
to the Investor a certificate or certificates evidencing issuance to the
Investor of the appropriate number of fully-paid and non-assessable shares of
Common Stock. The Company and the Investor shall comply with the conditions to
the sale set forth in Sections 9 and 10 hereof.

                   (C) If the Company has sent a Sale Notice pursuant to
paragraph (B) of this Section 2(b)(i), the Company agrees to advise the Investor
periodically as to the expected timing of the closing of the IPO. If at any time
the Company reasonably believes that shares of Common Stock will not be sold in
an IPO within the next thirty (30) days, the Company may send to the Investor an
Amended Sale Notice which will supersede the Sale Notice delivered under
2(b)(i)(B). Such Amended Sale Notice shall advise the Investor of the number of
shares of Preferred Stock that the Company has determined to sell to the
Investor, the Fair Market Value of each such share of Preferred Stock, the
purchase price for each such share of Preferred Stock and the Aggregate Purchase
Price. The Investor agrees to pay a purchase price for each share of Preferred
Stock equal to one-hundred twenty-five percent (125%) of the Fair Market Value
of a share of such Preferred Stock within thirty (30) days of the Investors
receipt of the Amended Sale Notice. The Investor shall deliver the payment for
such shares of Preferred Stock by a wire transfer of immediately available funds
or by a certified bank check payable to the order of the Company in the amount
of the Aggregate Purchase Price. Upon receipt of such payment by the Company on
a Business Day, the Investor will be deemed to be the holder of record of such
shares of Preferred Stock and the Company will promptly execute and provide to
the Investor a certificate or certificates evidencing issuance to the Investor
of the appropriate number of fully-paid and non-assessable shares of such
Preferred Stock. The Company and the Investor shall comply with the conditions
to the sale set forth in Sections 9 and 10 hereof.

              (ii) PURCHASE OF COMMON STOCK AFTER AN IPO.

                   (A) The Sale Notice relating to a Tranche Event that occurs
after an IPO will be sent to the Investor no sooner than fifty (50) days and no
later than sixty (60) days after the issuance of an announcement, a press
release or other publicity regarding the occurrence of the related Tranche Event
or twenty-five (25) Business Days after the Investor has reasonably withheld
consent to the issuance of the announcement, the press release or the other
publicity regarding the occurrence of the Tranche Event. The Sale Notice will
advise the investor that it must purchase shares of Common Stock in accordance
with this Agreement, that the Fair Market Value will be determined based upon
the Trading Period beginning on the specific date that was ten (10) Business
Days prior to the date of the Sale Notice and that the Investor must pay the
Aggregate Purchase Price on the tenth (10th) Business Day after the date of the
Sale Notice. The Investor agrees to pay a purchase price for each share of
Common Stock equal to one-hundred twenty-five percent (125%) of

                                      -9-

<PAGE>

the Fair Market Value of a share of Common Stock. The number of shares of Common
Stock that the investor will purchase will equal the Aggregate Purchase Price
divided by the product of 1.25 times the Fair Market Value of a share of Common
Stock, rounded down, if necessary, to the next whole number of shares.

                   (B) On the tenth (10th) Business Day after the date of the
Sale Notice the Investor shall deliver the payment for the shares of Common
Stock by a wire transfer of immediately available funds or by a certified bank
check payable to the order of the Company in the amount of the Aggregate
Purchase Price. Upon receipt of such payment by the Company, the Investor will
be deemed to be the holder of record of the shares of Common Stock and the
Company will promptly execute and provide to the Investor a certificate or
certificates evidencing issuance to the Investor of the appropriate number of
fully-paid and non-assessable shares of Common Stock. In addition, the Company
will advise the Investor of the calculation of the Fair Market Value of each
share of Common Stock, the purchase price paid by the Investor for each such
share of Common Stock and the number of shares of Common Stock that the Investor
has purchased and will remit to the Investor the difference, if any, between the
Aggregate Purchase Price and the product of the purchase price for each share of
Common Stock purchased by the Investor under this Section 2(b)(ii)(A) multiplied
by the number of shares of Common Stock purchased by the Investor. The Company
and the Investor shall comply with the conditions to the sale set forth in
Sections 9 and 10 hereof.

          (c) NONPERFORMANCE BY THE INVESTOR.  Any failure by the Investor to
acquire the Securities in compliance with the provisions of this Agreement,
including as a result of any failure of the Investor to satisfy the conditions
of Section 10 hereof, but excluding as a result of any failure of the Company to
satisfy the conditions of Section 9 hereof, may result in a termination of the
Collaboration Agreement in accordance with Section 19.2 of the Collaboration
Agreement; provided that no such termination shall occur if the Investor's
failure to pay for the Securities in accordance with the Agreement is caused by
a circumstance outside of the control of the Investor and the Investor's payment
for the Securities is delivered as soon as practicable but no later than twenty
(20) Business Days, or a period of time that is otherwise reasonably agreed to
by the parties, after delivery is required pursuant to this Section 2.

     3.   AUTHORIZATION OF SECURITIES.  At the time the Company provides the
Sale Notice or the Amended Sale Notice to the Investor, the Securities shall be
duly and validly authorized and reserved for issuance.

     4.   REPRESENTATIONS AND WARRANTIES OF THE COMPANY.  The Company hereby
represents and warrants that, as of the date of this Agreement:

          (a) CORPORATE ORGANIZATION.  The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware, and is duly qualified to conduct its business as a foreign corporation
in all jurisdictions where the failure to be so qualified would have an adverse
effect on the Company or its business.

                                      -10-

<PAGE>

          (b) CORPORATE AUTHORITY. The Company has all necessary corporate power
to execute, deliver and perform this Agreement subject to, in each instance, the
due authorization of the issuance of the Securities and the taking of all
required steps to effect the same.

          (c) CAPITALIZATION.  The Company's authorized capital stock consists
of (i) 52,005,095 shares of Common Stock, 5,672,475 of which are outstanding;
(ii) 1,334,000 shares of Class A Preferred Stock, 1,334,000 of which are
outstanding; (iii) 11,800,468 shares of Class B Preferred Stock, 11,320,314 of
which are outstanding; (iv) 21,065,000 shares of Class C Preferred Stock,
21,065,000 of which are outstanding; and (v) 2,000,000 shares of Class D
Preferred Stock, 571,429 of which are outstanding.  All outstanding shares of
capital stock are validly issued and outstanding, fully-paid and non-assessable.

Except as contemplated by this Agreement and as set forth on Schedule 4(c)
hereto, there are no outstanding rights of first refusal, warrants, options,
conversion privileges, preemptive rights, or other rights or agreements to
purchase or otherwise acquire or issue any equity securities of the Company.

          (d) SUBSIDIARIES.  The Company does not presently own, have any
investment in, or control, directly or indirectly, any Subsidiaries,
corporations, associations or other business entities.

          (e) VALIDITY OF SECURITIES.  The Securities, when issued, sold and
delivered in accordance with the terms of this Agreement and for the Aggregate
Purchase Price specified in the applicable Sale Notice or Amended Sale Notice,
shall be duly and validly issued, fully-paid and nonassessable.  If the
Securities are shares of Preferred Stock, the Common Stock issuable upon
conversion of such Preferred Stock, in accordance with the Company's Charter,
shall be, upon such issuance, duly and validly issued, fully-paid and non-
assessable.

          (f) FINANCIAL STATEMENTS.  The Company has made available to the
Investor the Company's audited financial statements for its most recent fiscal
year and unaudited financial statements for its most recent interim period, in
each case, to the extent available.  As of the date of this Agreement, the
financial statements provided are attached hereto as EXHIBIT C. The annual
financial statements have been prepared in accordance with GAAP and the interim
financial statements have been prepared in a manner consistent with the annual
financial statements (subject to normal year-end audit adjustments and the
omission of footnotes required by GAAP).

          (g)  AGREEMENTS; ACTIONS.

               (i)    Schedule 4(g)(i) hereto sets forth a list of agreements
and proposed agreements between the Company and any of its officers, directors,
Affiliates or any Affiliate thereof

               (ii)   Except as set forth in Schedule 4(g)(ii) hereto, there are
no agreements,

                                      -11-

<PAGE>

instruments or contracts to which the Company is a party or by which it is bound
which involve (A) obligations of, or payments to, the Company in excess of Two-
Hundred Fifty Thousand Dollars ($250,000), (B) the license for commercial
purposes of any patent, copyright, trade secret or other proprietary rights to
or by the Company or (C) any other material agreement.

               (iii)  Except as set forth in Schedule 4(g)(iii) hereto, the
Company has not (A) declared or paid any dividends, or authorized or made any
distribution upon or with respect to any class or series of its capital stock,
(B) incurred any indebtedness for money borrowed, (C) incurred any other
liabilities individually in excess of One-Hundred Twenty-Five Thousand Dollars
($125,000) or in excess of Two-Hundred Fifty Thousand Dollars ($250,000) in the
aggregate, other than obligations or liabilities of the Company for compensation
under employment, advisor or consulting agreements, (D) made any loans or
advances to any person, other than ordinary advances for travel expenses, (E)
sold, exchanged or otherwise disposed of any of its material assets or rights or
(F) agreed to any of the foregoing.

          (h) LITIGATION.  To the Company's knowledge, there are neither any
pending nor threatened suits, legal proceedings, claims or governmental
investigations against or with respect to the Company or its properties or
assets, or that question the validity of this Agreement or the right of the
Company to enter into this Agreement.  There is no judgment, decree or order of
any court in effect against the Company and the Company is not in default with
respect to any order of any governmental authority to which the Company is a
party or by which it is bound.

          (i) NO CONFLICT WITH OTHER INSTRUMENTS; COMPLIANCE WITH LAWS.  Subject
to obtaining authorization of the issuance of the Securities and subject to
Section 9 hereof, the execution, delivery and performance of this Agreement will
not result in any material violation of, be in material conflict with, or
constitute a material default under, with or without the passage of time or the
giving of notice (i) any provision of the Charter or the Bylaws; (ii) any
provision of any judgment, decree or order to which the Company is a party or by
which it is bound; (iii) any material contract, obligation or commitment to
which the Company is a party or by which it is bound; or (iv) any material
statute, rule or governmental regulation applicable to the Company.  The Company
is conducting its business in compliance with all material statutes, rules and
governmental regulations applicable to the Company, and has obtained all
licenses, permits and other governmental authorizations required thereby, where
the failure to do so would have a material adverse effect on the Company or its
business.

          (j) TITLE TO PROPERTIES; LIENS AND ENCUMBRANCES.  Except as set forth
in the Company's financial statements or Schedule 4(j) hereto, the Company has
good and marketable title to all of its properties and assets, both real and
personal, and has good title to all of its leasehold interests, in each case
subject to no mortgage, pledge, lien, security interest, conditional sale
agreement, encumbrance or charge.

          (k) CONFIDENTIAL AND PROPRIETARY INFORMATION.  Each employee of and
consultant to the Company with access to confidential or proprietary

                                      -12-

<PAGE>

information has executed a proprietary information agreement obligating such
employee or consultant to hold all of such information in confidence.

          (l) NO DEFAULTS; VIOLATIONS OR CONFLICTS.  Except as set forth in
Schedule 4(l) hereto, the Company is not in violation of any term or provision
of the Charter, the Bylaws, or any term or provision of any document
representing indebtedness or any mortgage, indenture, contract, agreement or
judgment which would have a material adverse effect on the Company or its
business.

          (m) INSURANCE.  The Company has in effect insurance covering risks
associated with its business in such amounts as are customary in its industry.

          (n) PRIOR REGISTRATION RIGHTS.  Except as set forth in Schedule 4(n)
hereto, the Company is under no contractual obligation to register under the
Securities Act any of its presently outstanding securities or any shares of
Common Stock into which such securities are convertible.

          (o) FULL DISCLOSURE.  The representations and warranties of the
Company contained in this Agreement and the answers to the questions provided to
Section 5(b)(i) hereof do not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made herein, in
light of the circumstances under which they were made, not misleading.

          (p) GOVERNMENTAL CONSENTS.  No consent, approval, order or
authorization of, or registration, qualification, designation, declaration or
filing with, any federal, state, local or provincial governmental authority on
the part of the Company is required in connection with the consummation of the
transactions contemplated by this Agreement, except for any filing required by
federal or state securities laws and except, under certain circumstances, for
filings and notifications under the Hart-Scott-Rodino Improvements Act of 1976,
as amended, where applicable.

          (q) CORPORATE DOCUMENTS.  The Charter and the Bylaws of the Company in
effect as of the date of this Agreement are in the forms attached hereto as
Exhibits A and B, respectively.

     5.   REPRESENTATIONS AND WARRANTIES OF THE INVESTOR.  The Investor hereby
represents and warrants that, as of the date of this Agreement:

          (a) AUTHORIZATION.  The Investor has all corporate power to enter into
this Agreement and to carry out all of the transactions contemplated hereby,
including the purchase of Securities for an aggregate amount of Twenty-Five
Million Dollars ($25,000,000) and in up to six (6) separate transactions.  The
execution, delivery and performance of this Agreement by the Investor and the
consummation of the transactions contemplated hereby have been duly authorized
by all requisite corporate action on the part of the Investor.  This Agreement
constitutes a valid and binding instrument of the Investor, enforceable in
accordance with its terms, subject, as to enforcement, to bankruptcy,
insolvency, reorganization and other laws of general applicability relating to
or affecting creditors' rights and to general equity principles.

                                      -13-

<PAGE>

          (b) SECURITIES REPRESENTATIONS.  The Investor will acquire the
Securities for purposes of investment for its own account and not with a view
to, or for resale in connection with, the distribution thereof, as those terms
are used in the Securities Act, and the rules and regulations promulgated
thereunder.  The Investor has been advised and acknowledges that it will not be
able to dispose of the Securities, or any interest therein, without first
complying with the relevant provisions of this Agreement, the Securities Act and
any applicable state securities laws.  The Investor also understands that the
provisions of Rule 144 promulgated under the Securities Act, permitting routine
sales of securities of certain issuers subject to the terms and conditions
thereof, are not currently available to it with respect to the Securities.  The
Investor acknowledges that, except as set forth in this Agreement, the Company
is under no obligation to register the Securities or to take any action to
assist the Investor in complying with the terms and conditions of any exemption
that might be available under the Securities Act or any state securities laws
with respect to sales of the Securities by the Investor in the future.

              (i)     The Investor believes that, as of the date of this
Agreement, it has received all of the information it considers necessary or
appropriate for deciding whether to purchase the Securities. The Investor
further represents that it has had an opportunity to ask questions and receive
answers from the Company regarding the terms and conditions of the offering of
the Securities pursuant to this Agreement and the business, properties,
prospects and financial condition of the Company.

              (ii)    The Investor represents that:  (A) the Investor has such
knowledge and experience in financial and business matters as to be capable of
evaluating the merits and risks of the Investor's prospective investments in the
Securities; (B) the Investor has the ability to bear the economic risk of its
prospective investments; and (C) the Investor is able, without materially
impairing its financial condition, to hold the Securities for an indefinite
period of time and to suffer complete loss on its investments.

              (iii)   The Investor is an "accredited investor," as that term is
defined in Rule 501 promulgated under the Securities Act.

              (iv)    The Investor either is (A) not an "Investment Company," as
that term is defined in the Investment Company Act or (B) excluded from the
definition of an Investment Company under Section 3(c)(1) of the Investment
Company Act.

              (v)     The Investor acknowledges that the representations,
agreements and acknowledgments set forth above are being given by the Investor
with the understanding that they will be relied upon by the Company and its
board of directors to claim the availability of the exemption from the
registration provisions of the Securities Act contained in Section 4(2) thereof
or Regulation D promulgated thereunder.

                                      -14-

<PAGE>

     6.   COVENANTS OF THE COMPANY.  The Company hereby covenants that, so long
as (x) the Investor owns any shares of Preferred Stock and (y) the Company has
not consummated an IPO, the Company shall furnish to the Investor the financial
statements and reports described in (a) and (b) of this section, such annual
financial statements to be prepared in accordance with GAAP and such interim
financial statements to be prepared in a manner consistent with the annual
financial statements (subject to normal year-end audit adjustments and the
omission of footnotes required by GAAP):

          (a) As soon as available, and in any event within one-hundred twenty
(120) days after the end of each fiscal year of the Company, a balance sheet of
the Company as of the end of such fiscal year and related statements of
operations, stockholders' equity and cash flows for such fiscal year, all in
reasonable detail and setting forth in comparative form the figures as of the
end of and for that fiscal year, which financial statements shall have been
audited; and

          (b) As soon as available, and in any event within sixty (60) days
after the end of each fiscal quarter of the Company, an unaudited balance sheet
and unaudited statements of operations and cash flows.

     7.   COVENANTS OF THE INVESTOR.

          (a) NOTIFICATION OF THE OCCURRENCE OF A TRANCHE EVENT, The Investor
agrees to promptly notify the Company when it becomes aware of the occurrence of
any Tranche Event other than through the receipt of notice from the Company.

          (b)  TRANSFER OF SECURITIES.

               (i)    The Investor agrees that it will not Transfer Securities
at any time during any Lock-up Period unless (A) the Investor receives the
express prior written consent of the Company, at the Company's sole discretion
and subject to appropriate Transfer restrictions, (B) the Transfer is a Transfer
to a holder of any of the Company's capital stock and the Transfer takes place
after the Investor provides the Company with prior notice of the Transfer and
before (x) the sale of shares of Common Stock in an IPO and (y) the earlier of
the end of the Term of the Research Program or the delivery by the Investor to
the Company of a notice of termination of the Term of the Research Program, (C)
the Transfer is a Transfer after the end of the Term of the Research Program and
prior to the sale of shares of Common Stock in an IPO to the Company at the
purchase price that a bona fide third party offered to pay the Investor for the
Securities or to the third party if the Company determines not to purchase the
Securities and expresses prior written consent to the Transfer of the Securities
to the third party, which consent shall not be unreasonably withheld, and the
third party agrees to restrictions of Transfer in this Section 7, in a written
agreement reasonably acceptable to the Company, or (D) the Transfer is a
Transfer to the purchaser of all of the outstanding capital stock of the
Investor or all or substantially all of the assets of the Investor, including
every right and interest such entity may have in the Collaboration Agreement, or
to a Subsidiary of the Investor and the Transferee assumes all of the Investor's
obligations, covenants and

                                      -15-

<PAGE>

agreements under this Agreement, including the restrictions on Transfer in this
Section 7, in a written agreement reasonably acceptable to the Company. Upon
such a Transfer to a Subsidiary, the Investor agrees to repurchase the
Securities from the Subsidiary immediately prior to a cessation of the
Subsidiary's status as a Subsidiary of the Investor. If any Lock-up Period is in
effect at the time the Collaboration Agreement is terminated pursuant to its
terms, the Lock-up Period shall terminate one year after such termination.

              (ii)    In addition to Section 7(b)(i), until the end of the
Restriction Period, the Investor agrees that any sales of shares of Common Stock
acquired under this Agreement, or shares of Common Stock obtained upon the
conversion of Preferred Stock acquired under this Agreement, will be in an
amount that does not exceed in any ninety (90) day period the greater of' (i)
two and one-half percent (2 1/2%) of the Investor's ownership of shares of
Common Stock at the time of the sale or (ii) the average weekly reported volume
of trading in shares of Common Stock on all national securities exchanges and/or
reported through the automated quotation system of a registered securities
association during the four calendar weeks preceding the sale except as
otherwise agreed to in writing by the Company.

              (iii)   The Investor agrees to hold the Securities subject to
all of the applicable provisions of the Securities Act and the Charter and the
Bylaws in effect as of the date of this Agreement.

              (iv)    Until the first approval of a PLA (as defined in the
Collaboration Agreement) by an Agency (as defined in the Collaboration
Agreement) of a Collaboration Product, the Investor shall give the Company
prompt written notice of any proposed Transfer of the Securities and shall not
proceed with any such proposed Transfer unless otherwise permitted under this
Agreement.

              (v)     The Investor agrees that certificates representing the
Securities issued to it pursuant hereto may bear the following or a similar
legend:

     THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A CONTRACTUAL
     LIMITATION ON THEIR SALE, ASSIGNMENT, PLEDGE, HYPOTHECATION, ENCUMBRANCE,
     TRANSFER OR OTHER DISPOSITION DESCRIBED IN THE STOCK PURCHASE AGREEMENT
     DATED JULY ___, 1997.  IN ADDITION, THE SHARES HAVE BEEN ACQUIRED FOR
     INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
     AS AMENDED (THE "SECURITIES ACT"), OR THE SECURITIES LAWS OF ANY STATE.
     NEITHER THE SHARES NOR ANY INTEREST OR PARTICIPATION IN THE SHARES MAY BE
     SOLD, ASSIGNED, PLEDGED, HYPOTHECATED, ENCUMBERED OR IN ANY OTHER MANNER
     TRANSFERRED OR DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
     STATEMENT FOR SUCH SHARES UNDER THE SECURITIES ACT, UNLESS, IN THE OPINION
     (WHICH SHALL BE IN FORM AND

                                      -16-

<PAGE>

     SUBSTANCE SATISFACTORY TO THE CORPORATION) OF COUNSEL SATISFACTORY TO THE
     CORPORATION, SUCH REGISTRATION IS NOT REQUIRED.

          (c) CONFIDENTIAL INFORMATION.  The Investor's obligations with respect
to disclosure of certain information are set forth in Article 17 of the
Collaboration Agreement.

          (d) AGREEMENTS WITH UNDERWRITERS.  In connection with any public
offering of shares of Common Stock, the Investor agrees to enter into a written
agreement with the underwriter(s) if the managing underwriter(s) demands or
requests such an agreement from the Investor and in such form and containing
such provisions as are required by the managing underwriter(s) (except that such
provisions will not be less favorable to the Investor than the provisions of any
agreements entered into by the managing underwriter(s) with other holders of
securities issued by the Company) to preclude the Investor from directly or
indirectly offering to sell, contracting

                                      -17-

<PAGE>

to sell or otherwise disposing of any shares of Common Stock, or any securities
convertible into or exchangeable for shares of Common Stock for a specified
period of time after completion of the public offering.

          (e) ACQUISITIONS OF SECURITIES OF THE COMPANY.  The Investor agrees
that from the date hereof until the expiration of the Collaboration Agreement
(or, if the Collaboration Agreement is terminated earlier pursuant to its terms,
one year after such termination), it will not, directly or indirectly, acquire,
offer to acquire, agree to acquire, become the beneficial owner of or obtain any
rights in respect of any capital stock of the Company, by purchase or otherwise,
except as contemplated by this Agreement or as otherwise agreed to in writing by
the Company, and except through the acquisition for business purposes unrelated
to the Company of all of the outstanding capital stock or all or substantially
all of the assets of a holder of any of the Company's capital stock.

     8.   REGISTRATION RIGHTS.

          (a) PIGGYBACK REGISTRATION RIGHTS.  Subject to Section 7(b)(i) and
Section 7(b)(ii) hereof, if the Company plans to file a registration statement
under the Securities Act on a Form S-3 to register any shares of Common Stock
for sale by it in an underwritten public offering during the Restriction Period
or for sale by it (except in connection with any dividend reinvestment plan,
stock option plan stock purchase plan, savings or similar plan) or any of its
stockholders at any time after the end of the Restriction Period other than on a
shelf registration statement (the "Piggyback Registration Statement"), the
Company shall provide to the Investor and any Transferee under Section
7(b)(i)(D) (referred to jointly in this Section 8 as the "Investor") hereof the
right to include the shares of Common Stock acquired under this Agreement on the
Piggyback Registration Statement, if the Investor is the stockholder of record
of the shares of Common Stock at such time and is unable to sell any shares of
Common Stock acquired under this Agreement pursuant to Rule 144(k) (or any
successor rule) under the Securities Act by providing the Investor with at least
twenty (20) days notice prior to the effectiveness of such registration
statement.  At the written request of the Investor, given within ten (10) days
after receipt of such notice, the Company will use reasonable efforts to cause
all of the shares of Common Stock for which registration shall have been
requested to be included in the Piggyback Registration Statement.

          (b) DEMAND REGISTRATION.  If the Investor is unable to sell shares of
Common Stork within eighteen (18) months after the end of the Restriction Period
pursuant to Rule 144(k) (or a successor rule) under the Securities Act or on a
Piggyback Registration Statement, the Investor shall have the right to require
the Company to file one registration statement under the Securities Act on a
Form S-3, provided such registration form is available to the Company, to
register shares of Common Stock acquired under this Agreement for sale in a
public offering that is not to be made on a continuous or delayed basis pursuant
to Rule 415 (or a successor rule) under the Securities Act and that is expected
to yield net proceeds to the Investor of at least Five Million Dollars
($5,000,000), as specified in a written notice from the Investor to the Company.

                                      -18-

<PAGE>

              (i)     Following the Company's receipt of any notice under this
Section 8(b), the Company shall use its best efforts to register under the
Securities Act, as soon as reasonably practicable, the number of shares of
Common Stock specified by the Investor in such notice (or such lesser number as
the managing underwriter(s) in such offering believes will not unduly jeopardize
the success of the offering); provided, however, that the Company may delay the
filing of the registration statement for as long as

                      (A) the request for registration pursuant to this Section
8(b) would require the Company to include in the registration statement on the
filing date or on the expected effective date audited financial statements which
are not yet required to be filed with the Commission under the Exchange Act; or

                      (B) the Company's board of directors reasonably
determines that the disclosure required in the registration statement or the
pricing of the offering would adversely affect the Company or its ability to
engage in a planned registered public offering or in any other planned activity.

              (ii)    In the event that the Investor makes a demand for
registration as described in this Section 8(b), the Company shall have the right
to register other shares of Common Stock in the registration statement;

PROVIDED, HOWEVER, that such shares shall not be included to the extent provided
in Section 8(f) below, if applicable, and in all other situations, such shares
(other than the Original Registration Stock) shall not be included to the extent
that the Investor determines in good faith that the inclusion of such shares
will interfere with the successful marketing of the Investor's shares to be
included therein; PROVIDED, FURTHER, that, if the number of shares to be so
included exceeds the number of the Investor's shares included therein, such
registration shall be deemed to be a registration pursuant to Section 8(a)
hereof.

              (iii)   The managing underwriter(s) for any underwritten public
offering pursuant to this Section 8(b), shall be mutually acceptable to the
Company and the Investor.

          (c) In connection with any registration statement prepared pursuant to
this Section 8:

              (i)     the Company shall:

                      (A) use its best efforts to prepare and file with the
Commission the registration statement and use its best efforts to cause such
registration statement to become effective as soon as practicable, provided that
before filing a registration statement or prospectus or any amendments or
supplements thereto, the Company shall furnish to the counsel selected by the
Investor, which shall be reasonably acceptable to the Company, and the counsel
selected by any managing underwriter(s) copies of all such documents proposed to
be filed, which documents will be subject to the review of such counsel;

                                      -19-

<PAGE>

                      (B) use its best efforts to prepare and file with the
Commission such amendments and supplements to such registration statement as may
be necessary to comply with the provisions of the Securities Act;

                      (C) furnish, or instruct the printer to furnish, to the
Investor such number of copies of the registration statement, each amendment and
supplement thereto, the prospectus included in such registration statement
(including each preliminary prospectus) and such other documents as the Investor
may reasonably request in order to facilitate the disposition of the registered
shares of Common Stock;

                      (D) use its best efforts to register or qualify the
registered shares of Common Stock under such other securities or blue sky laws
of such jurisdictions as the Investor or the managing underwriter(s) in the
offering reasonably deems appropriate, provided that the Company will not be
required to subject itself to taxation in any such jurisdiction, qualify itself
to do business as a foreign corporation in any such jurisdiction, or consent to
general service of process in any such jurisdiction, where it would not
otherwise be so subject, need to be so qualified or need to so consent but for
this requirement;

                      (E) use its best efforts to cause all of such registered
shares of Common Stock to be listed on each securities exchange on which
securities of the same class as the registered shares of Common Stock are then
listed;

                      (F) take all actions Customary for such offerings as the
Investor or any managing underwriter(s) reasonably request in order to expedite
or facilitate the disposition of the registered shares of Common Stock being
sold; and

                      (G) in the event of the issuance of any stop order
suspending the effectiveness of a registration statement, or of any order
suspending or preventing the use of any related prospectus or suspending the
qualification of any security included in such registration statement for sale
in any jurisdiction, use its best efforts promptly to obtain the withdrawal of
such order, and

              (ii)    the Investor shall be required to furnish the Company with
all relevant information concerning the proposed method of sale of the shares of
Common Stock, and such other information as may be reasonably required by the
Company properly to prepare and file such registration statement in accordance
with applicable provisions of the Securities Act and the rules and regulations
thereunder.  Upon request of the Company, such information shall be furnished by
the Investor in writing.

          (d) The Investor shall bear all of its expenses in connection with any
registration statement under this Section 8, including the fees and expenses of
its counsel.  The Investor shall also bear its pro rata share of all of the
other expenses in connection with the preparation and filing of any registration
statement under this Section 8, any registration or qualification under the
securities laws of states in which the offering will be made under such
registration statement, any

                                      -20-

<PAGE>

filing fee of the National Association of Securities Dealers, Inc. relating to
such offering and any underwriters' or brokers' commission, provided, however,
that the Company shall pay half of the Investor's pro rata share of such other
expenses, except for any brokers' commissions, in an offering that is not
underwritten.

          (e) In connection with any public underwritten offering in which the
Investor's shares are registered, the Company and the Investor shall enter into
a written agreement with the managing underwriter(s) in such form and containing
such provisions as are customary in the securities business for such an
arrangement between such managing underwriter(s) and companies of the Company's
size and investment stature, including indemnification.

          (f) In the event that the proposed offering under this Section 8 is an
offering by the Company that is, in whole or in part, an underwritten public
offering of shares of Common Stock, and the managing underwriter(s) determines
and advises in writing that the inclusion in the underwritten public offering of
all of the shares of Common Stock owned by the Selling Stockholders would
interfere with the successful marketing (including pricing) of the shares, the
number of the Selling Stockholders' shares to be included in such underwritten
public offering shall be reduced, based upon the number of shares requested by
the Selling Stockholders to be registered in such underwritten public offering
first, pro rata among the holders of Other Shares; second, if necessary, by the
Investor's shares of Common Stock; third, if necessary, pro rata, among the
holders of the Class C Preferred Stock and the Warrant Shares; fourth, if
necessary, pro rata among the holders of the Original Registration Stock; and
lastly, if necessary, among the Company's shares requested by the Company to be
registered.

     9.   CONDITIONS OF THE INVESTOR'S OBLIGATIONS TO ACQUIRE THE SECURITIES.
The obligations of the Investor to acquire the Securities in connection with
each Tranche Event are subject to the following, any of which the Investor may
waive in its discretion:

          (a) OPINION OF` COUNSEL.  The Company shall provide to the Investor
with the Sale Notice or the Amended Sale Notice, as applicable, an opinion of
the Company's counsel, in form and substance reasonably acceptable to the
Investor, that the Securities, when sold and delivered in accordance with this
Agreement, will be duly authorized, validly issued, fully-paid and non-
assessable and, if the Securities are shares of Preferred Stock, the Common
Stock issuable upon conversion of the Preferred Stock, when issued and delivered
upon such conversion in accordance with the Charter, as amended, will be duly
authorized, validly issued, fully-paid and non-assessable.

          (b) REPRESENTATIONS AND WARRANTIES.  The Company shall update the
representations and warranties in Section 4 hereof as of the date of the Sale
Notice or the Amended Sale Notice, as applicable.

          (c) SECURITIES LAWS.  The Company shall have complied with the federal
and state securities laws applicable to the offer and sale of the Securities to
the Investor.

                                      -21-

<PAGE>

          (d) COMPLIANCE CERTIFICATE.  The Company shall have delivered to the
Investor a certificate, dated as of the date of the Sale Notice or the Amended
Sale Notice, as applicable, signed by the Company's President, certifying that
the conditions to be performed by the Company set forth in this Section 9 have
been satisfied.

          (e) CERTIFIED DOCUMENTS.  There shall have been delivered to the
Investor copies of the Charter and the Bylaws (in each case, as amended or
restated through the date of the Sale Notice), certified by the Secretary of the
Company as complete and correct copies thereof as of the date of the Sale Notice
or the Amended Sale Notice, as applicable.

          (f) COURT ORDERS.  There shall not be in effect any injunction or
restraining order issued by any court of competent jurisdiction in any action or
proceeding against the consummation of the sale and purchase of the Securities
under this Agreement.

          (g) THIRD PARTY AND GOVERNMENTAL CONSENTS AND APPROVALS.  The Company
shall have obtained any third party and governmental consents and approvals
necessary for the consummation of the transactions contemplated hereby.

     10.  CONDITIONS OF THE COMPANY'S ISSUANCE OF SECURITIES UPON RECEIPT OF
INVESTOR'S PAYMENT THEREFOR.  The obligations of the Company to issue
certificates for the Securities upon receipt of the Aggregate Purchase Price in
connection with each Tranche Event are subject to the following, any of which
the Company may waive in its discretion:

          (a) REPRESENTATIONS AND WARRANTIES.  The representations and
warranties of the Investor contained in Section 5 shall be true on and as of the
date that payment for the Securities is given to the Company.

          (b) COVENANTS OF THE INVESTOR.  The Investor shall be in compliance
with its covenants in Section 7 hereof.

          (c) THIRD PARTY AND GOVERNMENTAL CONSENTS AND APPROVALS.  The Investor
shall have obtained any third party and governmental consents and approvals
necessary for the consummation of the transactions contemplated hereby.

          (d) COMPLIANCE CERTIFICATES.  The Investor shall have delivered to the
Company dated as of the date of the payment of the Aggregate Purchase Price,
signed by an authorized representative of the Investor, certifying that the
conditions set forth in this Section 10 have been satisfied.

     11.  POST-SALE COVENANTS OF THE COMPANY.

          (a) SECURITIES LAWS COMPLIANCE.  The Company shall make any filings
required by the securities laws of any applicable jurisdiction within the
required time period.

                                      -22-

<PAGE>

          (b) CONFIDENTIAL AND PROPRIETARY INFORMATION.  Unless otherwise
determined by the board of directors, the Company shall require all future
officers, directors and employees of the Company and its Subsidiaries to execute
the Company's standard form of proprietary information agreement.

     12.  TERMINATION AND SURVIVAL.

          This Agreement shall terminate upon a termination of the Collaboration
Agreement. Sections 7, 12 and 13(f) of this Agreement shall survive any
termination of this Agreement which results from a termination of the
Collaboration Agreement by the Company for cause pursuant to Section 19.2 of the
Collaboration Agreement as a result of actions taken by the Investor.  If the
Collaboration Agreement shall be terminated for any other reason, Sections
7(b)(iii), 7(b)(iv), 7(b)(v), 7(c), 7(d), 8(a), 8(c), 8(d), 8(e), 9(c), 11(a),
12 and 13(f) of this Agreement shall survive such termination.

     13.  MISCELLANEOUS.

          (a) EXISTING OWNERSHIP OF COMMON STOCK AND CLASS B PREFERRED STOCK.
The parties acknowledge and agree that the shares of Common Stock and Class B
Preferred Stock, and the right to acquire shares of Common Stock upon the
conversion of such Class B Preferred Stock, owned by the Investor as of the date
of this Agreement, and any other rights arising as a result of such ownership of
shares of Common Stock or Class B Preferred Stock, are not subject to this
Agreement.

          (b) AMENDMENTS AND WAIVERS.  Except as otherwise provided in this
Agreement, any provision hereof may be changed, waived, discharged or terminated
only by an instrument in writing signed by the Company and the Investor.  Any
change, waiver, discharge or termination effected in accordance with this
subsection shall be binding upon the Company and the Investor and upon any
Transferee to which this Agreement or the Securities are Transferred pursuant to
Section 13(d) hereof or Section 7(b) of this Agreement, respectively.

          (c) NECESSARY ACTION TO EFFECT THE AGREEMENT.  The parties agree to
take all necessary action to effect the transactions contemplated by this
Agreement including making all of the required filings and notifications under
the Hart-Scott-Rodino Improvements Act of 1976, as amended, if applicable, and
any other required filings or notices with other governmental agencies Each
party will bear its own expenses associated with any such filings and
notifications.

          (d) TRANSFERABILITY.  Neither the Investor nor the Company may
Transfer this Agreement, or any of the rights or obligations hereunder, unless
it is Transferred to the purchaser of all of the outstanding capital stock of
the entity or all or substantially all of the assets of the entity, including
every right and interest such entity may have in the Collaboration Agreement.
The Investor and the Company further agree that, prior to any Transfer of this
Agreement in accordance

                                      -23-

<PAGE>

with this Section 13(d), the Investor or the Company, as applicable, will give
written notice to the other party. This Agreement will be binding upon any
Transferees to which this Agreement is Transferred.

          (e) PUBLICITY. The parties agree to cooperate with respect to the
issuance of any publicity about the occurrence of a Tranche Event.  Within five
(5) Business Days after the Company receives notice from the Investor or
otherwise becomes aware of the occurrence of a Tranche Event, the Company shall
give notice to the Investor of a request for the consent of the Investor to an
announcement, press release or other publicity about the occurrence of a Tranche
Event.  The Investor shall advise the Investor whether it consents to the
requested disclosure, which consent may not be unreasonably withheld, within
five (5) Business Days after its receipt of the notice. Notwithstanding the
Investors' failure to consent, the Company shall have the right to announce,
issue a press release or otherwise publicize the occurrence of a Tranche Event
to the extent necessary to comply with securities laws or listing or similar
requirements.  Once the Investor has consented to an announcement, press release
or other publicity of the occurrence of a Tranche Event, the announcement, press
release or other publicity must be issued within ten (10) Business Days of such
consent unless otherwise agreed to by the parties and either party may make
disclosures which do not differ materially from the agreed upon disclosure.

          (f) LAW GOVERNING.  This Agreement will be governed by, and construed
and enforced in accordance with, the internal laws of the State of Delaware.

          (g) NOTICES.  Unless otherwise provided, all notices, requests,
demands and other communications required or permitted under this Agreement will
be in writing and will be deemed to have been duly made and received: (i) upon
personal delivery or confirmed facsimile to the party to be notified; (ii) three
(3) Business Days after deposit with the United States Post Office, by
registered or certified mail, postage prepaid, addressed as set forth below; or
(iii) one (1) Business Day after deposit for overnight delivery with Federal
Express or another reputable overnight courier, shipping prepaid, addressed as
set forth below:

               (i)  If to the Company, then to:
                    GenVec, Inc.
                    12111 Parklawn Drive
                    Rockville, MD 20852

                    Attn: President

                    With a copy to:

                    Attn: Chief Financial Officer

              (ii)  If to the Investor, then to:
                    Warner-Lambert Company

                                      -24-

<PAGE>

                    2800 Plymouth Road
                    Ann Arbor, Michigan 48105

                    Attn:     Vice President and Chairman
                              Park-Davis Research Division

                    With a copy to:

                    Warner-Lambert Company
                    201 Tabor Road
                    Morris Plains, NJ 07950

                    Attn: Vice President and General Counsel

Either party may change the address to which communications are to be sent by
giving five (5) Business Days' advance notice of such change of address to the
other party in conformity with the provisions of this Section 13(g).

          (h) HEADINGS.  The headings in this Agreement are for purposes of
reference only and will not affect the meaning or construction of any of the
provisions hereof

          (i) EXECUTION; COUNTERPARTS.  This Agreement may be executed in any
number of counterparts, each of which will be deemed to be an original as
against any party whose signature appears on such counterpart, and all of which
will together constitute one and the same instrument. This Agreement will become
binding when one or more counterparts of this Agreement, individually or taken
together, bear the signatures of all of the parties to this Agreement.

IN WITNESS WHEREOF, the parties have executed this Stock Purchase Agreement as
of the date first above written.

                              WARNER-LAMBERT COMPANY

                              By:
                                 -------------------------------------
                                    Name: Anthony Wild, Ph.D.
                                    Title: President
                                             Worldwide Pharma Sector

                              GENVEC

                              By:
                                 -------------------------------------
                                    Paul H. Fischer, Ph.D..
                                    President and Chief Executive Officer

                                      -25-<PAGE>

                                                                    EXHIBIT 10.7

                                LICENSE AGREEMENT

     This LICENSE AGREEMENT (the "Agreement") effective as of May 31, 1996 (the
"Effective Date"), is entered by and between Scios Inc., a Delaware corporation,
with principal offices at 2450 Bayshore Parkway, Mountain View, California 94043
("Scios"), and GenVec, Inc., a Delaware corporation, having a principal place of
business at 12111 Parklawn Drive, Rockville, Maryland 20852 ("GenVec").

                                    RECITALS

     A. Scios is the sole and exclusive owner of certain Patent Rights and
Know-How (as such terms are defined below) relating to vascular endothelial
growth factor (VEGF) 121 and nucleic acid sequences encoding VEGF 121, and the
use thereof, and related subject matter;

     B. GenVec desires to obtain an exclusive license to the Patent Rights and
Know-How in the Field (as defined below) and Scios is willing to grant such a
license to GenVec, on the terms and conditions herein;

     C. GenVec and Scios each wish to cooperate to facilitate the development of
proprietary VEGF products, as set forth herein;

     D. Of even date herewith, Scios and GenVec have entered into a Stock
Warrant Agreement pursuant to which GenVec will grant to Scios a warrant to
purchase shares of GenVec common stock; and

     E. Of even date herewith, Scios and GenVec have entered into a Stock
Purchase Agreement (attached hereto as Exhibit D) pursuant to which Scios will
purchase shares of GenVec Class D Convertible Preferred Stock.

     NOW, THEREFORE, Scios and GenVec agree as follows:

1.   DEFINITIONS

     1.1  "AFFILIATE" means any corporation or other entity which is directly or
indirectly controlling, controlled by or under the common control of a party
hereto. For the purpose of this Agreement, "control" shall mean the direct or
indirect ownership of at least fifty percent (50%) of the outstanding shares or
other voting rights of the subject entity to elect directors, or if not meeting
the preceding, any entity owned or controlled by or owning or controlling at the
maximum control or ownership right permitted in the country where such entity
exists.

[*]=CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

<PAGE>

     1.2  "COMPETING PRODUCT" shall mean any product in the Field sold by a
person other than (a) GenVec, (b) a GenVec sublicensee of the Licensed
Technology, (c) Genentech, Inc., or (d) a sublicensee of Genentech's patent
rights with respect to VEGF, in each case, which if sold by GenVec would be a
Licensed Product.

     1.3  "CONFIDENTIAL INFORMATION" shall mean (i) any proprietary or
confidential information or material in tangible form disclosed hereunder that
is marked as "confidential" at the time it is delivered to the receiving party,
or (ii) proprietary or confidential information disclosed orally hereunder which
is identified as confidential or proprietary when disclosed and such disclosure
of confidential information is confirmed in writing within thirty (30) days by
the disclosing party.

     1.4  "CORE COUNTRIES" shall mean the United States, Canada, Mexico, Japan,
United Kingdom, France, Germany and Italy.

     1.5 "DERIVED" shall mean a DNA sequence based on the human VEGF gene which
(i) is a fragment isolated from the human VEGF gene, which fragment encodes a
peptide with biological activity substantially functionally equivalent to the
native VEGF protein, *

     1.6  "EQUITY VALUE" shall mean an amount for the purchase of shares of
GenVec stock, which is equal to one hundred twenty five percent (125%) of the
fair market value of such stock, with such fair market value determined based on
the share price on the date of actual purchase, unless GenVec enters into a
written agreement to sell such equity to the purchasing party in the future and
the share price on the actual date of purchase is lower than the share price at
the date such agreement is executed, in which event the fair market value of
such equity for purposes of this Section 1.6 shall be based on the share price
on the date such agreement is executed.

     1.7  "EXCESS EQUITY PURCHASE AMOUNT" shall mean any amount received by
GenVec from a corporate partner in connection with an agreement for the
development or commercialization of a Licensed Product for the purchase of
shares of GenVec stock which is greater than the Equity Value of such stock.

     1.8 "FIELD" shall mean gene therapy using a DNA sequence encoding all or
part of the gene for vascular endothelial growth factor (VEGF), or a *

     1.9  "LICENSED PRODUCT" shall mean any product containing a DNA sequence
from the VEGF gene (*) or any product containing a DNA sequence Derived
therefrom or a product within the scope of a Valid Claim within the Patent
Rights.

    1.10  "LICENSED TECHNOLOGY" means the Know-How and Patent Rights.

          1.10.1  "KNOW-HOW" shall mean any and all technical information,
materials (including without limitation, biological materials), processes,
procedures, compositions, devices, methods, formulas, protocols, techniques,
designs, drawings, and other technical data which is

                                      -2-

<PAGE>

owned, in whole or part, or controlled by Scios or its Affiliates during the
term of this Agreement, which is necessary or useful for the development,
manufacture, use or sale of Licensed Products. Know-How shall not include any
inventions included in the Patent Rights, and shall not include any business
information, such as market research or business analysis.

          1.10.2  "PATENT RIGHTS" means (i) the patent applications and patents
listed on Exhibit A hereto, and (ii) all patent applications and patents
relating to a DNA sequence encoding all or part of a gene for VEGF or a sequence
Derived therefrom, or methods of use thereof, or methods of making or use of a
gene for VEGF or, a sequence Derived therefrom, in each case, which is owned, in
whole or part, or controlled by Scios or its Affiliates during the term of this
Agreement including, without limitation, Scios' interest in any Joint
Inventions; and all divisions, continuations, continuations-in-part, and
substitutions of any of the preceding; all foreign patent applications
corresponding to any of the preceding applications or patents; and all U.S. and
foreign patents issuing on any of the preceding applications, including
extensions, reissues, and re-examinations.

     1.11  "MANUFACTURING COSTS" shall mean (i) all direct and indirect costs
related to the manufacture of Licensed Products, including without limitation,
costs for personnel, materials, quality control, regulatory compliance,
administrative expenses, subcontractors, fixed and variable manufacturing
overhead costs and business unit or division costs reasonably allocable to the
manufacture, packaging and labeling of Licensed Products, and the like, as
determined and allocated in accordance with generally accepted accounting
principles (GAAP), consistently applied, excluding costs for excess
manufacturing capacity not reasonably related to projected demand for Licensed
Products, or (ii) with respect to Licensed Products purchased from a third party
vendor, reasonable amounts actually paid to the vendor for such Licensed
Products.

     1.12 "NET PROFIT" shall mean any Excess Equity Purchase Amount received by
GenVec for the sale of GenVec stock during the term of this Agreement, and with
respect to Licensed Products, the Net Revenues received by GenVec with respect
to such Licensed Products, less:

          (a) with respect to Net Revenues subject to Section 1.13 (c), (d) and
(e), where GenVec or a third party which is not a sublicensee of GenVec
manufactures Licensed Products for sale by GenVec, an amount for such
manufacturing equal to the greater of (i) * of Net Sales with respect to such
Licensed Products, or (ii) * of the Manufacturing Costs related to such Licensed
Products; and

          (b) with respect to Net Revenues subject to Section 1.13 (d), any
expenses incurred or accrued in connection with the unit packaging, labeling,
marketing, sale or other disposition of the Licensed Products by GenVec, and
general and administrative expenses relating to the preceding, as determined and
allocated in accordance with generally accepted accounting principles.

     1.13 "NET REVENUES" means the gross revenues received by GenVec for:

                                      -3-

<PAGE>

          *

For the avoidance of doubt, it is understood and agreed that Net Revenues shall
not include any amount received by GenVec from a third party for (i) the
purchase of GenVec stock at or below the Equity Value thereof, (ii) Research and
Development Payments, or (iii) reimbursement for patent expenses or other
reimbursements incurred after the execution of a written agreement between
GenVec and a third party providing for reimbursement of such expenses. It is
further understood and agreed that where GenVec has entered into a co-promotion
agreement with a third party with respect to Licensed Products pursuant to which
both parties have the right to commercialize such Licensed Products, Net
Revenues shall only include those revenues received by GenVec with respect to
such Licensed Products which GenVec has the contractual right to retain. It is
further understood and agreed that Net Revenues shall not include Withholding
Taxes (as defined in Section 4.4 below) paid with respect to sales of Licensed
Products to governmental entities pursuant to applicable law.

     1.14  "NET SALES" means the amounts received by GenVec and its sublicensees
with respect to sales of Licensed Products to independent third parties, less:
(i) rebates, credits and cash, trade and quantity discounts, actually taken,
(ii) excise taxes, sales, use, value added, and other consumption taxes and
other compulsory payments to governmental authorities, actually paid, (iii) the
cost of any shipping packages and packing, if billed separately, (iv) insurance
costs and outbound transportation charges prepaid or allowed, (v) import and/or
export duties and tariffs actually paid, (vi) amounts allowed or credited due to
returns or uncollectible amounts, and (vii) amounts paid to independent third
parties for intellectual property rights to manufacture, use, import or sell
Licensed Products. GenVec and its sublicensees shall not transfer Licensed
Products for consideration other than cash or cash equivalents without providing
Scios fair compensation therefore consistent with this Agreement; provided,
GenVec shall provide such compensation in a form reasonably acceptable to Scios.

     1.15  "RESEARCH AND DEVELOPMENT PAYMENTS" means those payments received by
GenVec from a third party licensee of a Licensed Product that are specifically
intended to support research and development on such Licensed Product,
including: (i) payments to fund the actual fully burdened direct costs of
research and development by GenVec to be performed subsequent to the execution
by GenVec of a written agreement with a third party providing for the
reimbursement of such expenses, plus reasonable GenVec overhead, including
general and administrative expenses, allocated to such research and development
in accordance with GAAP, consistently applied; (ii) payments to cover the actual
payments by GenVec to third parties for research and development relating to the
Licensed Product; and (iii) payments for any other expenses which GenVec can
demonstrate are directly related to such research and development and which can
be reasonably allocated in accordance with GAAP, consistently applied.

     1.16  "TRANSFER SALES" means the amounts received by GenVec with respect to
sales of Licensed Products to its sublicensees, less: (i) rebates, credits and
cash, trade and quantity discounts, actually taken, (ii) excise taxes, sales,
use, value added, and other consumption taxes and other compulsory payments to
governmental authorities, actually paid, (iii) the cost of any shipping

                                      -4-

<PAGE>

packages and packing, if billed separately, (iv) insurance costs and outbound
transportation charges prepaid or allowed, (v) import and/or export duties and
tariffs actually paid, (vi) amounts allowed or credited due to returns or
uncollectible amounts, and (vii) amounts paid to independent third parties for
intellectual property rights to manufacture, use, import or sell Licensed
Products. GenVec shall not transfer Licensed Products to its sublicensees for
consideration other than cash or cash equivalents without providing Scios fair
compensation therefore consistent with this Agreement, in a form reasonably
acceptable to Scios.

     1.17  "TERRITORY" means all countries of the world.

     1.18  "VALID CLAIM" means (i) a claim of an issued and unexpired patent
claiming a human VEGF cDNA which has not been held unenforceable or invalid by a
court or other governmental agency of competent jurisdiction in an unappealed or
unappealable decision, and which has not been disclaimed or admitted to be
invalid or unenforceable through reissue or otherwise, or (ii) a pending claim
of a patent application claiming a human VEGF cDNA or a sequence Derived
therefrom.

2.   LICENSE

     2.1  LICENSE GRANT.  Scios hereby grants to GenVec an exclusive, worldwide
license under the Licensed Technology, with the right to grant and authorize
sublicenses, to make, have made, import, have imported, use, sell, offer for
sale and otherwise exploit Licensed Products in the Field in the Territory.

     2.2  DELIVERY OF KNOW-HOW.  Within five (5) days after the Effective Date,
Scios shall deliver to GenVec the biological materials listed on Exhibit B
hereto and the sequence and genetic map of the VEGF 121 cDNA. Within forty-five
(45) days after the Effective Date, knowledgeable representatives of the parties
shall meet to discuss the existing Know-How and shall agree on which Know-How
Scios shall deliver to GenVec, and the schedule of delivery and form thereof. At
least semi-annually during the term of the Agreement, Scios shall provide to
GenVec all Know-How developed or generated during the preceding six (6) month
period.

     2.3  COOPERATION.  It is understood and agreed that the parties intend to
confer and cooperate to aid each other, without charge, in the development and
commercialization of products within the Patent Rights. The parties shall
negotiate in good faith the scope and nature of such activities, but agree to do
at least the following:

          2.3.1  SCIOS ACTIVITIES.  Scios shall: (i) provide GenVec with
protocols for Scios' * (iii) meet with GenVec prior to GenVec's pre-IND meeting
with the FDA, to discuss strategy for such meeting; * Such discussions will be
participated in by Scios representatives with appropriate expertise in the
relevant topics. The discussions shall include updates to GenVec as the
understanding of these areas develops.

                                      -5-

<PAGE>

          2.3.2  GENVEC ACTIVITIES.  GenVec shall, to the extent permitted by
its contracts with third parties, allow Scios to inspect GenVec's GMP
manufacturing facility for Licensed Products and keep Scios generally informed
regarding the development of Licensed Products. During the interactions between
Scios and GenVec under this Section 2.3, GenVec shall not disclose to Scios
Confidential Information of GenVec except as it may pertain to a Licensed
Product, or any Confidential Information obtained from a third party.

          2.3.3  LEVEL OF COOPERATION.  Unless otherwise agreed, neither party
shall have any obligation to provide services to the other pursuant to this
Section 2.3 or Section 3.10 in excess of an aggregate of * per calendar quarter.

          2.3.4  TERMINATION.  Except as expressly provided in this Section
2.3.4, the foregoing cooperative activities (but not activities subject to
Section 3.10) shall terminate, at GenVec's discretion, if Scios, itself or with
a third party, commences a program to develop either (i) a VEGF product outside
the Field, or (ii) any product not based on VEGF which GenVec reasonably
believes would compete with a Licensed Product. Scios shall promptly notify
GenVec of its intent to commence any such program, and GenVec may notify Scios
that it wishes to terminate the cooperative activities subject to this Section
2.3, and in such event such activities shall terminate effective immediately.

3.   CONSIDERATION

     3.1 WARRANTS. In partial consideration of the license granted herein, of
even date herewith GenVec has granted Scios a warrant to purchase shares of
GenVec stock pursuant to the terms of the Stock Warrant Agreement attached
hereto as Exhibit C.

     3.2  PROFIT SHARING.  Subject to Section 3.4 below, in partial
consideration of the license granted herein, *

     3.3  MINIMUM ROYALTY.  Notwithstanding Section 3.2 above, with respect to
sales of Licensed Products (including sales of Licensed Products in connection
with a co-promotion relationship) made in countries where there is a Valid Claim
of an issued patent within the Patent Rights covering such Licensed Products,
subject to Section 3.4, GenVec shall pay to Scios no less * All payments made
under this Section 3.3 and Section 3.4 below shall be fully creditable against
any amounts due Scios under Section 3.2.

     3.4  PAYMENT REDUCTIONS.  In the event that a Licensed Product is made,
used or sold in a country where there is a competing product in the Field, the
amounts due Scios pursuant to Sections 3.2 and 3.3 shall be reduced as follows:

          3.4.1  ONE COMPETING PRODUCT.  If any Competing Product is sold in a
country and such Competing Product accounts for * or more of the total value of
the sales (in local currency) of

                                      -6-

<PAGE>

products in the Field in such country, then subject to Section 3.4.2 below,
GenVec shall pay to Scios * of the amounts otherwise due pursuant to Sections
3.2 and 3.3 above with respect to sales of Licensed Products in such country.

          3.4.2  MORE THAN ONE COMPETING PRODUCT.  If two (2) or more Competing
Products are sold in a country, and (i) one such Competing Product accounts for
* or more of the total value of the sales (in local currency) of products in the
Field in such country, and (ii) the combined sales of all Competing Products in
the Field in such country exceed * of total value of the sales (in local
currency) of products in the Field, then GenVec shall pay to Scios * of the
amounts otherwise due pursuant to Sections 3.2 and 3.3 above with respect to
sales of Licensed Products in such country.

     3.5  COMBINATION PRODUCTS.  In the event that a Licensed Product is sold in
combination with one or more other product(s) (excluding any products which have
no therapeutic utility) or active therapeutic agent(s) which are not Licensed
Products, Net Revenues from such sales for purposes of calculating the amounts
due under Sections 3.2, 3.3 and 3.4 above shall be calculated by multiplying the
Net Revenues of that combination by the fraction A/(A + B), where A is the gross
selling price of the Licensed Product sold separately and B is the gross selling
price of the other product or active therapeutic agent(s) sold separately. In
the event that no such separate sales are made of the Licensed Product or other
active therapeutic agent or product, Net Revenues with respect to such
combination product shall be as reasonably determined by the parties based on an
allocation between such Licensed Product and such other product or active
therapeutic agent(s), based upon their relative importance and proprietary
protection. Notwithstanding the above, the provisions of this Section 3.5 shall
not apply to Net Revenues to the extent an offset is taken for any corresponding
Net Sales with respect to Section 1.14(vii).

     3.6  OTHER TECHNOLOGY AND PRODUCTS.  It is understood and agreed that in
the event GenVec enters into an agreement with a third party which provides such
third party rights to the Licensed Technology and/or Licensed Products and
intellectual property other than the Licensed Technology and/or products other
than Licensed Products, pursuant to which it receives license fees and/or
milestone payments with respect to (i) intellectual property other than the
Licensed Technology for use in the development or commercialization of products
other than Licensed Products, or (ii) products other than Licensed Products, the
portion of such amounts which constitute Net Profits shall be as reasonably
determined by the parties based on an allocation between the amounts
attributable to the Licensed Technology or Licensed Product and such other
intellectual property or product, based upon their relative importance and
proprietary protection, and GenVec shall only pay to Scios that portion of such
amounts reasonably attributable to the Licensed Technology or Licensed Product,
as the case may be.

     3.7  COMMERCIAL IMPRACTICABILITY.  Notwithstanding the above, in the event
that GenVec believes that the payments set forth in Sections 3.2 or 3.3 above
would make the sale of Licensed Products commercially impracticable it may
notify Scios, and in such event the parties shall negotiate in good faith a
reduction in such payments.

                                      -7-

<PAGE>

     3.8  ONE PAYMENT.  No more than one payment shall be due with respect to a
sale of a particular Licensed Product. No multiple payments shall be payable
because any Licensed Product, or its manufacture, sale or use is covered by more
than one Valid Claim. No amount shall be payable under Sections 3.2 or 3.3 above
with respect to Licensed Products distributed for use in research and/or
development, in clinical trials, or as promotional samples where such samples
are provided at or below cost.

     3.9  PAYMENT TERM.  Payments due under this Article 3 shall be payable on a
country-by-country and Licensed Product-by-Licensed Product basis. In countries
where there exists a Valid Claim of an issued patent within the Patent Rights
covering a particular Licensed Product, such payments shall be payable until the
expiration of the last-to-expire issued Valid Claim within the Patent Rights in
such country covering such Licensed Product. If no Valid Claim of an issued
patent within the Patent Rights covering a particular Licensed Product exists in
a country, payments shall be payable in such country until the earlier of (i)
the fifteenth anniversary of the Effective Date, or (ii) the tenth anniversary
of the first commercial sale of a Licensed Product in such country; provided, in
the event that a patent within the Patent Rights containing a Valid Claim issues
in such country, then GenVec shall make payments with respect to such Valid
Claim for the period set forth in the second sentence above.

     3.10  INFORMATION REGARDING GENE THERAPY.  In partial consideration of the
rights granted herein, GenVec shall provide to Scios during the term of this
Agreement general insights and information concerning the decision-making and
development processes utilized by GenVec in the development of gene therapy
products. Such discussions will be participated in by GenVec representatives
with appropriate expertise in the relevant topics. The discussions shall include
updates to Scios as the understanding of these areas develops. During the
interactions between Scios and GenVec subject to this Section 3.10, GenVec need
not disclose to Scios any Confidential Information of GenVec except as it may
pertain to a Licensed Product, or any Confidential Information obtained from a
third party. During the period of cooperative activities subject to Section 2.3,
GenVec may provide such insights and information in the context of discussions
regarding the development of a Licensed Product. Thereafter, GenVec may provide
such insight and information to Scios in the context of another product or
general education regarding the gene therapy field. Following termination of the
cooperative activities subject to Section 2.3, GenVec shall not be required to
meet with Scios representatives more than twice per calendar year to provide
information under this Section, or participate in any such meetings more than
five (5) years following the date of termination of the cooperative activities
subject to Section 2.3. Such meeting may be held in person or by telephone or
video conference.

4.   PAYMENTS

     4.1  PAYMENTS.  GenVec shall pay amounts due Scios pursuant to Article 3
within * after the last day of the calendar quarter in which they are received;
provided, any amounts due with respect to Net Revenues subject to Section 1.13
(a) or (b) shall be paid to Scios within * after such amounts are received by
GenVec. All payments due hereunder shall be made in U.S. dollars, and

                                      -8-

<PAGE>

shall be made by bank wire transfer in immediately available funds to an account
designated by Scios.

     4.2  CURRENCY CONVERSION.  If any currency conversion shall be required in
connection with the calculation of payments hereunder, such conversion shall be
made using the selling exchange rate for conversion of the foreign currency into
U.S. dollars, quoted for current "buy" transactions for purchasing U.S. dollars
as reported in THE WALL STREET JOURNAL for the last business day of the calendar
quarter to which such payment pertains.

     4.3  RESTRICTIONS ON PAYMENT.  To the extent and as long as the laws and/or
regulations in force in any country prohibit the payment, conversion or
remittance of any of the payments as hereby contemplated, GenVec's obligations
under Article 4 may be discharged by the deposit thereof to the account of
GenVec, or its designee, in any commercial bank or trust company selected by
Scios located in such country; provided, that no infraction of law or regulation
occurs in making such deposit. If due to restrictions or prohibitions imposed by
national or international authority, payments cannot be made as aforesaid, the
parties shall consult with a view to finding a prompt and acceptable solution,
and GenVec will, from time to time, deposit such monies as Scios may lawfully
direct, at no additional out-of-pocket expense to GenVec and with no further
obligation to Scios.

     4.4  WITHHOLDING TAXES.  All amounts required to be paid to Scios pursuant
to this Agreement may be paid with deduction for withholding for or on account
of any taxes (other than taxes imposed or measured by net income) or similar
governmental charge imposed on such payment by a jurisdiction other than the
United States ("Withholding Taxes"). GenVec agrees to take reasonable efforts to
structure its business arrangements in order to minimize the Withholding Taxes,
but shall have no obligation to follow any course of action or enter into any
business relationship which would have an adverse impact on GenVec or its
Affiliates or sublicensees, as reasonably determined by GenVec. Upon Scios'
request, GenVec shall provide Scios a certificate evidencing payment of any
Withholding Taxes hereunder.

5.   REPORTS AND RECORDS

     5.1  NET PROFIT REPORTS.  GenVec shall deliver to Scios within * after the
end of each calendar quarter in which Licensed Products are sold a written
report setting forth in reasonable detail, on a Licensed Product-by-Licensed
Product basis, the calculation of the amounts payable to Scios for such calendar
quarter, including the quantities of Licensed Products sold and the Net Revenues
and Net Profits with respect thereto. Such reports shall be Confidential
Information of GenVec subject to Article 7 herein.

     5.2  INSPECTION OF BOOKS AND RECORDS.  GenVec shall maintain accurate books
and records which enable the calculation of amounts payable hereunder to be
verified. GenVec shall retain the books and records for each quarterly period
for * after the submission of the corresponding report under Section 5.1 hereof.
Upon * prior notice to GenVec, independent accountants selected by

                                      -9-

<PAGE>

Scios, reasonably acceptable to GenVec, after entering into a confidentiality
agreement with GenVec in a form reasonably acceptable to GenVec, may have access
to the books and records of GenVec to conduct a review or audit once per
calendar year, for the sole purpose of verifying the accuracy of GenVec's
payments and compliance with this Agreement. The accountants shall report to
Scios only whether there has been an underpayment and, if so, the amount
thereof. Such access shall be permitted during GenVec's normal business hours at
agreed times during the term of this Agreement and for * after the expiration or
termination of this Agreement. Any such inspection or audit shall be at Scios'
expense, however, in the event an inspection reveals underpayment of * or more
in any audit period, GenVec shall pay the costs of the inspection.

6.   DILIGENCE

     6.1  REASONABLE EFFORTS.  GenVec agrees to use reasonable efforts to
diligently develop and commercialize at least one Licensed Product and obtain
such approvals as may be necessary for the sale of such Licensed Products in the
United States and such other worldwide markets as GenVec elects to commercialize
the Licensed Products. GenVec's efforts shall be comparable to those efforts
GenVec makes with respect to its other products of comparable value, stage of
development and patent protection. The selection of Licensed Products for
development and commercialization shall be in the sole discretion of GenVec, and
GenVec may satisfy its obligations under this Article 6 itself or through a
sublicensee. GenVec shall notify Scios within * after the first commercial sale
of each Licensed Product.

     6.2  FIRST CLINICAL DOSING.  GenVec agrees to (i) use reasonable efforts to
dose at least one (1) human patient with a Licensed Product under a United
States IND sponsored by GenVec by the third anniversary of the Effective Date,
or (ii) by the third anniversary of the Effective Date, expend at least * on the
development of a Licensed Product. In the event that GenVec fails to accomplish
both milestones, Scios may, within sixty (60) days of such date, provide GenVec
notice that it intends to terminate the Agreement pursuant to Section 12.2;
provided, however, in such event GenVec may present Scios evidence that it has
acted diligently and in good faith to meet the milestones but failed due to
reasons outside GenVec's control, and in such case Scios shall not have the
right to terminate the Agreement.

7.   CONFIDENTIALITY; PUBLICATIONS

     7.1  CONFIDENTIAL INFORMATION.  Except as expressly provided herein, the
parties agree that, for the term of this Agreement and for * thereafter, the
receiving party shall keep completely confidential and shall not publish or
otherwise disclose and shall not use for any purpose except for the purposes
contemplated by this Agreement any Confidential Information furnished to it by
the disclosing party hereto pursuant to this Agreement, except that to the
extent that it can be established by the receiving party by competent proof that
such Confidential Information:

                                      -10-

<PAGE>

          (i) was already known to the receiving party, other than under an
obligation of confidentiality, at the time of disclosure;

          (ii) was generally available to the public or otherwise part of the
public domain at the time of its disclosure to the receiving party;

          (iii) became generally available to the public or otherwise part of
the public domain after its disclosure and other than through any act or
omission of the receiving party in breach of this Agreement;

          (iv)  was independently developed by the receiving party; or

          (v) was lawfully disclosed to the receiving party by a person other
than a party hereto.

     7.2  PERMITTED USE AND DISCLOSURES.  Each party hereto may use or disclose
information disclosed to it by the other party to the extent such use or
disclosure is reasonably necessary in filing or prosecuting patent applications,
prosecuting or defending litigation, complying with laws, governmental
regulations or court orders submitting information to tax or other governmental
authorities, conducting pre-clinical research and development or clinical
trials, making a permitted sublicense or otherwise exercising its rights
hereunder, provided that if a party is required to make any such disclosure of
another party's confidential information, other than pursuant to a
confidentiality agreement, it will give reasonable advance notice to the latter
party of such disclosure and, save to the extent inappropriate in the case of
patent applications, will use reasonable efforts to secure confidential
treatment of such information prior to its disclosure (whether through
protective orders or otherwise).

     7.3  PUBLIC DISCLOSURES.  Except as expressly provided in this Article 7,
no disclosure or public announcement or other disclosure to third parties
concerning the existence of this Agreement shall be made, either directly or
indirectly, by any party to this Agreement, except as may be legally or
contractually required or as may be required for recording purposes, without
first obtaining the approval of the other party and agreement upon the nature
and text of such announcement of disclosure, which approval shall not be
unreasonably withheld. The party required to make any such public announcement
shall use its reasonable efforts to inform the other party of the proposed
announcement in reasonably sufficient time prior to public release, and shall
use its reasonable efforts to provide the other party with a written copy
thereof, in order to allow such other party to comment upon such announcement.
Once a particular disclosure has been approved, further disclosures which do not
differ materially therefrom may be made without obtaining any further consent of
the other party.

     7.4  CONFIDENTIAL TERMS.  Except as expressly provided herein, each party
agrees not to disclose any terms of this Agreement to any third party without
the consent of the other party; provided, reasonable disclosures may be made as
required by securities or other applicable laws, or

                                      -11-

<PAGE>

to actual or prospective investors or corporate partners, or to a party's
accountants, attorneys and other professional advisors.

8.   REPRESENTATIONS AND WARRANTIES

     8.1 SCIOS. Scios represents and warrants that: (i) it is a corporation
duly organized, validly existing and in good standing under the laws of
Delaware; (ii) when executed and delivered, this Agreement will become valid and
binding on Scios, and enforceable against Scios in accordance with its terms;
(iii) the execution, delivery and performance of this Agreement have been duly
authorized by all necessary corporate action on the part of Scios; (iv) it is
the sole and exclusive owners of all right, title and interest in the Patent
Rights and the Know-How; (v) it has the right to grant the rights and licenses
granted herein; (vi) the Patent Rights and Know-How are free and clear of any
lien, encumbrance, security interest or restriction on license; (vii) it has not
previously granted, and will not grant during the term of this Agreement, any
right, license or interest in or to the Patent Rights and Know-How, or any
portion thereof, inconsistent with the license granted to GenVec herein; and
(viii) there are no threatened or pending actions, suits, investigations, claims
or proceedings in any way relating to the Patent Rights or Know-How.

     8.2  GENVEC.  GenVec represents and warrants that: (i) it is a corporation
duly organized validly existing and in good standing under the laws of the State
of Delaware; (ii) when executed and delivered, this Agreement will become valid
and binding on GenVec, and enforceable against GenVec in accordance with its
terms; (iii) the execution, delivery and performance of this Agreement have been
duly authorized by all necessary corporate action on the part of GenVec, and
(iv) as of the Effective Date, without conducting any inquiry, GenVec is not
aware of threatened or pending actions, suits, investigations, claims or
proceedings in any way relating to issued patents which GenVec necessarily must
acquire license or other rights to in order to commercialize the Licensed
Technology.

9.   INTELLECTUAL PROPERTY

     9.1 OWNERSHIP. Title to all inventions and other intellectual property
made solely by or on behalf of GenVec during the term of the Agreement shall be
owned by GenVec. Title to all inventions and other intellectual property made
solely by or on behalf of Scios during the term of the Agreement shall be owned
by Scios. Title to all inventions and other intellectual property made jointly
by or on behalf of Scios and GenVec during the term of the Agreement shall be
jointly owned by GenVec and Scios (each a "Joint Invention"). Inventorship of
inventions and other intellectual property rights conceived and/or reduced to
practice by the parties and ownership rights with respect thereto, shall be
determined in accordance with the patent laws of the United States.

     9.2  PATENT PROSECUTION.

                                      -12-

<PAGE>

          9.2.1  SCIOS RESPONSIBILITIES.  Except as set forth in Sections 9.2.2
and 9.2.3, Scios shall, at its sole expense, have the right to control the
preparation, filing, prosecution and maintenance of the Patent Rights, and any
interferences, re-examinations, reissues and oppositions relating thereto, using
patent counsel of its choice. Scios shall consult with GenVec regarding the
conduct of all such activities, by providing GenVec an opportunity to review and
provide input on all proposed submissions to any patent office at least thirty
(30) days before submittal, and shall include in such applications such claims
as GenVec may reasonably request. Scios shall keep GenVec fully informed as to
the status of such patent applications by promptly providing GenVec copies of
all communications relating to such patent applications that are received from
or sent to any patent office, including without limitation, notice of all
interferences, reissues, re-examinations or oppositions.

          9.2.2  SCIOS FAILURE TO PURSUE.  In the event Scios fails to file or
having filed fails to further prosecute or maintain any patent applications or
patents within the Patent Rights, or conduct any interferences, re-examinations,
reissues or oppositions with respect thereto, then GenVec shall have the right
to prepare, file, prosecute and maintain such patent applications and patents in
such countries worldwide it deems appropriate, and conduct any interferences,
re-examinations, reissues or oppositions, at its sole expense, using patent
counsel of its choice. In any such event, with respect to (a) patent
applications filed before May 1, 1996, and patents issuing on patent
applications claiming a priority date earlier than May 1, 1996, GenVec shall
have no obligation to pay to Scios any amount with respect to any Licensed
Product covered solely by such a patent application or patent, and with respect
to (b) other patent applications and patents within the Patent Rights except
those subject to Section 9.2.3, GenVec shall have the right to offset against
payments due Scios under this Agreement an amount equal * the patent-related
expenses incurred by GenVec in connection with conducting any of the foregoing
activities with respect to such patent applications and patents.

          9.2.3  JOINT INVENTIONS.

                 (a) The parties will cooperate to file, prosecute and maintain
patent applications covering the Joint Invention(s) in the Core Countries (in
European countries through a European Patent Convention application) and other
countries agreed by the parties. The parties shall agree which parties shall be
responsible for conducting such activities with respect to a particular Joint
Invention and agree on a plan for such activities. The party conducting such
activities shall keep the other party fully informed as to the status of such
patent matters, including, without limitation, by providing the other party the
opportunity, at the other party's expense, to review and comment on any
documents relating to the Joint Invention which will be filed in any patent
office at least thirty (30) days before such filing, and promptly providing the
other party copies of any documents relating to Joint Invention which the party
conducting such activities receives from such patent offices, including notice
of all interferences, reissues, reexaminations, oppositions or requests for
patent term extensions. Subject to Section 9.2.3(b) below, the parties will
share equally all reasonable expenses and fees associated with the filing,
prosecution, issuance and maintenance of

                                      -13-

<PAGE>

any patent application and resulting patent for a Joint Invention in the Core
Countries and other agreed countries in accordance with the agreed plan or a
mutually agreed modification thereof.

                 (b) In the event that either party wishes to seek patent
protection with respect to any Joint Invention outside the Core Countries, it
shall notify the other party hereto. If both parties wish to seek patent
protection with respect to such Joint Invention in such country or countries,
activities shall be subject to Section 9.2.3(a) above. If only one party wishes
to seek patent protection with respect to such Joint Invention in such country
or countries, it may file, prosecute and maintain patent applications and
patents with respect thereto, at its own expense. In any such case, the party
declining to participate in patent application or patent relating to such
activities shall not grant any third party a license under its interest in the
applicable patent application or patent claiming such Joint Intervention without
the prior written consent of the other party.

          9.2.4  GENVEC RESPONSIBILITIES.  GenVec shall, at its sole expense,
have the right to control the preparation, filing, prosecution and maintenance
of any patent applications and patents solely owned by it, and any
interferences, re-examinations, reissues and oppositions relating thereto, using
patent counsel of its choice.

     9.3  COPIES.  Upon request by GenVec, Scios shall provide to GenVec a copy
of any patent applications within the Patent Rights filed by Scios or its
Affiliates during the term of this Agreement promptly after such application is
filed. GenVec shall treat such patent applications as Confidential Information
of Scios until such applications are published.

     9.4  ENFORCEMENT.  If either party hereto becomes aware that any Patent
Rights (including, without limitation, patents claiming any Joint Invention) are
being or have been infringed by any third party or are subject to a declaratory
judgment action, or that any Know-How has been misappropriated by a third party,
such party shall promptly notify the other party hereto in writing describing
the facts relating thereto in reasonable detail.

          9.4.1  SCIOS.  Except as set forth in Section 9.4.3 below, Scios shall
have the initial right, but not the obligation, to institute, prosecute and
control any such action, suit or proceeding (an "Action") at its expense, using
counsel of its choice, and GenVec shall cooperate with Scios in connection with
any such Action, at Scios' expense; provided, Scios may not enter into any
settlement which admits that any of the Patent Rights as it relates to the Field
or any jointly owned patent claiming a Joint Invention is invalid or
unenforceable. Any amounts recovered from third parties in any such Action shall
be used first to reimburse Scios for its costs and expenses associated with such
Action (including, without limitation, attorneys' and experts' fees), and the
remainder shall be divided between the parties as follows: with respect to any
Action other than one concerning a Joint Invention, GenVec shall receive * of
such remainder and Scios shall receive * and with respect to any Action
concerning a Joint Invention other than one relating to gene therapy, GenVec
shall receive * of such remainder and Scios shall receive *

                                      -14-

<PAGE>

          9.4.2  GENVEC.  In the event Scios fails to initiate or defend any
Action involving the Patent Rights within * days of receiving notice of any
alleged infringement with respect to which one or more third parties has made
sales of allegedly infringing products of at least * or an aggregate of at least
*, GenVec shall have the right, but not the obligation, to initiate such an
Action, at its expense; provided, GenVec may not enter into any settlement which
admits that any of the Patent Rights are invalid or unenforceable. Any amounts
recovered from third parties in any such Action shall be used first to reimburse
GenVec for its costs and expenses associated with such Action (including,
without limitation, attorneys' and experts' fees) and the remainder shall be
divided by the parties with GenVec receiving * of such remainder and Scios
receiving *

          9.4.3  JOINT INVENTIONS RELATING TO GENE THERAPY.  GenVec shall have
the initial right, but not the obligation, to institute, prosecute and control,
at its expense, any such Action with respect to any patent application or patent
claiming a Joint Invention relating to gene therapy, using counsel of its
choice, and Scios shall cooperate with GenVec in connection with any such
Action, at GenVec's expense; provided, GenVec may not enter into any settlement
which admits that any patent claiming a Joint Invention is invalid or
unenforceable. Any amounts recovered from third parties in any such Action shall
be used first to reimburse GenVec for its costs and expenses associated with
such Action (including, without limitation, attorneys' and experts' fees), and
the remainder shall be divided between the parties, with Scios receiving * of
such remainder and GenVec receiving *

     9.5  INFRINGEMENT CLAIMS.  If the practice by GenVec of the license granted
with respect to the Licensed Technology results in any allegation or claim of
infringement of an intellectual property right of third party against GenVec or
Scios (an "Infringement Claim"), GenVec shall have the exclusive right to defend
any such claim, suit or proceeding, at its own expense, by counsel of its own
choice and shall have the sole right and authority to settle any such suit, and
shall indemnify Scios therefore pursuant to Sections 11.1 and 11.3; provided,
however, Scios shall cooperate with GenVec, at GenVec's reasonable request in
connection with the defense of such claim pursuant to Section 11.3. GenVec shall
be entitled to offset such costs and expenses (including attorneys and
professional fees) incurred in connection with any such proceeding against any
amounts it would otherwise owe Scios under Article 3, up to a maximum of * of
the amounts due Scios.

     9.6  PATENT TERM EXTENSIONS.  With respect to patents within the Patent
Rights, if Scios has not itself earlier applied for a patent extension or other
governmental equivalent available under applicable law with respect to a
particular patent, at GenVec's request following approval of a Licensed Product,
Scios shall, unless Scios or another Scios licensee is developing a product
within the scope of such patent and such product has entered Phase II clinical
trials as of the date of GenVec's request and Scios notifies GenVec that it
intends to file a request for a patent extension or equivalent based on such
other product, designate GenVec (or its designee) as Scios' agent for obtaining
an extension of such patent or governmental equivalent which extends the
exclusivity of any of the patent subject matter where available in any country
in the world, or if not feasible, at GenVec's option, permit GenVec to file in
Scios' name to obtain such extension for GenVec or its sublicensee(s), at
GenVec's expense. Furthermore, Scios and its Affiliates agree to provide

                                      -15-

<PAGE>

reasonable assistance to facilitate GenVec's or its sublicensees' efforts to
obtain any such extension. In the event that GenVec elects not to seek such an
extension or equivalent in any country it shall notify Scios, and Scios shall
have the right to seek such an extension or equivalent in such country, at its
expense.

     9.7  GENE THERAPY DISCLOSURES.  As of the Effective Date, GenVec has
disclosed to Scios certain publications relating to gene therapy which GenVec
believes may be relevant to the commercialization of the Licensed Technology.

10.  DISPUTE RESOLUTION

     10.1 MEDIATION. If a dispute arises out of or relates to this contract,
or the breach thereof, and if said dispute cannot be settled through
negotiation, the parties agree first to try in good faith to settle the dispute
by mediation under the Commercial Mediation Rules of the American Arbitration
Association before resorting to arbitration, litigation, or some other dispute
resolution procedures.

     10.2  ARBITRATION.  Scios and GenVec agree that any dispute or controversy
arising out of, in relation to, or in connection with this Agreement, or the
validity, enforceability, construction, performance or breach thereof, which is
not resolved by mediation shall be settled by binding arbitration in Rockville,
Maryland, under the then-current Commercial Arbitration Rules and Supplemental
Procedures for Large, Complex Disputes of the American Arbitration Association
by one (1) arbitrator appointed in accordance with such Rules. The arbitrators
shall determine what discovery will be permitted, based on the principle of
limiting the cost and time which the parties must expend on discovery; provided,
the arbitrators shall permit such discovery as they deem necessary to achieve an
equitable resolution of the dispute. The decision and/or award rendered by the
arbitrator shall be written, final and non-appealable and may be entered in any
court of competent jurisdiction. The parties agree that, any provision of
applicable law notwithstanding, they will not request, and the arbitrator shall
have no authority to award, punitive or exemplary damages against any party. The
costs of any arbitration, including administrative fees and fees of the
arbitrator, shall be shared equally by the parties. Each party shall bear the
cost of its own attorneys' fees and expert fees.

11.  INDEMNIFICATION

     11.1 GENVEC. GenVec shall indemnify, defend and hold harmless Scios and
its directors, officers, employees and agents (each a "Scios Indemnitee") from
and against any and all liabilities, damages, losses, costs or expenses
(including reasonable attorneys' and professional fees and other expenses of
litigation and/or arbitration) (a "Liability") resulting from any claim, suit or
proceeding brought by a third party against a Scios Indemnitee, arising out of
or in connection with (i) any misrepresentation with regard to, or breach of,
any of the representations and warranties of GenVec set forth in Section 8.2, or
(ii) the use by GenVec or its sublicensees of the biological materials

                                      -16-

<PAGE>

provided by Scios to GenVec, or the development, manufacture, use and sale of
Licensed Products by GenVec or its sublicensees, except, in each case, to the
extent due to the negligence or willful misconduct of Scios.

     11.2  SCIOS.  Scios shall indemnify, defend and hold harmless GenVec and
its directors, officers, employees and agents (each a "GenVec Indemnitee") from
and against any and all liabilities, damages, losses, costs or expenses
(including reasonable attorneys' and professional fees and other expenses of
litigation and/or arbitration) (a "Liability") resulting from any claim, suit or
proceeding brought by a third party against a GenVec Indemnitee, arising out of
or in connection with any misrepresentation with regard to, or breach of, any of
the representations and warranties of Scios set forth in Section 8.1, except, to
the extent due to the negligence or wilful misconduct of GenVec.

     11.3  PROCEDURE.  In the event that any Indemnitee intends to claim
indemnification under this Article 11 it shall promptly notify the other party
in writing of such alleged Liability. The indemnifying party shall have the
right to control the defense thereof. The affected Indemnitees shall cooperate
fully with the indemnifying party and its legal representatives in the
investigation and conduct of any Liability covered by this Article 11. The
Indemnitee shall not, except at its own cost, voluntarily make any payment or
incur any expense with respect to any claim, suit or Liability, or make any
admission of liability or attempt to settle any claim without the prior written
consent of the indemnifying party, which such party shall not be required to
give.

12.  TERM AND TERMINATION

     12.1 TERM. The term of this Agreement shall commence on the Effective
Date, and unless earlier terminated as provided in this Article 12, shall
continue in full force and effect on a country-by-country and Licensed Product-
by-Licensed Product basis until there are no remaining payment obligations in a
country, at which time the Agreement shall expire in its entirety in such
country. Notwithstanding the above, upon the expiration of this Agreement in any
country, GenVec shall have a non-exclusive, irrevocable, fully paid-up right and
license to use and exploit the Know-How for any purpose.

     12.2  TERMINATION FOR CAUSE.  If either party materially breaches this
Agreement, the other party may elect to give the breaching party written notice
describing the alleged breach. If the breaching party has not cured such breach
or is diligently seeking to cure such breach within sixty (60) days after
receipt of such notice, the notifying party will be entitled, in addition to any
other rights it may have under this Agreement, to terminate this Agreement
effective immediately; provided, however, if either party receives notification
from the other of a material breach and if the party alleged to be in default
notifies the other party in writing within forty-five (45) days of receipt of
such default notice that it disputes the asserted default, the matter will be
submitted to dispute resolution as provided in Article 10 of this Agreement. In
such event, the nonbreaching party shall not have the right to terminate this
Agreement until it has been determined in an arbitration

                                      -17-

<PAGE>

proceeding that the other party materially breached this Agreement, and the
breaching party fails to cure such breach within ninety (90) days after the
conclusion of such arbitration proceeding.

     12.3  TERMINATION FOR INSOLVENCY.  Either party may terminate this
Agreement if the other becomes the subject of a voluntary or involuntary
petition in bankruptcy or any proceeding relating to insolvency, receivership,
liquidation, or composition or the benefit of creditors, if that petition or
proceeding is not dismissed with prejudice within sixty (60) days after filing.

     12.4  TERMINATION FOR IMPRACTICABILITY.  GenVec may terminate this
Agreement with sixty (60) days written notice to Scios if GenVec or a GenVec
sublicensee encounters significant technical, safety or efficacy difficulties in
the development, manufacture or commercialization of a Licensed Product within
the Patent Rights which would make the commercialization of such a Licensed
Product commercially impracticable.

     12.5  EFFECT OF TERMINATION.

          12.5.1  ACCRUED RIGHTS AND OBLIGATIONS.  Termination of this Agreement
for any reason shall not release any party hereto from any liability which, at
the time of such termination, has already accrued to the other party or which is
attributable to a period prior to such termination, nor preclude either party
from pursuing any rights and remedies it may have hereunder or at law or in
equity which accrued or are based upon any event occurring prior to such
termination.

          12.5.2  RETURN OF CONFIDENTIAL INFORMATION.  Upon any termination of
this Agreement, each party shall promptly return to the other party all
Confidential Information received from the other party (except one copy of which
may be retained for archival purposes).

          12.5.3  STOCK ON HAND.  In the event this Agreement is terminated for
any reason, until six (6) months after the effective date of such a termination
GenVec and its sublicensees shall have the right to sell or otherwise dispose of
the stock of any Licensed Product subject to this Agreement then on hand,
subject to Articles 4 and 5.

          12.5.4  SUBLICENSEES.  In the event of any termination of this
Agreement any sublicensees granted by GenVec shall remain in force and effect
and shall be assigned by GenVec to Scios, provided, however, that the financial
obligations of each sublicense to Scios shall be limited to the amounts GenVec
would have been obligated to pay to Scios for the activities of such sublicensee
pursuant to this Agreement.

          12.5.5  COMPETING PRODUCTS.  If Scios terminates this Agreement
pursuant to Sections 12.2 or 12.3, GenVec may not commercialize a Licensed
Product within the scope of a Valid Claim without paying to Scios the royalties
due pursuant to Article 3, unless Scios commences the development or
commercialization of a Licensed Product in the Field, itself or with a third
party.

                                      -18-

<PAGE>

     12.6  SURVIVAL.  Sections 9.1, 9.2.3, 9.2.4, 9.5, 12.5 and 12.6, and
Articles 4 (with respect to Licensed Products sold prior to such termination or
pursuant to Section 12.5.3), 5, 7, 8, 10, 11 and 13 of this Agreement shall
survive termination of this Agreement for any reason.

13.  MISCELLANEOUS

     13.1  GOVERNING LAW.  This Agreement and any dispute arising from the
performance or breach hereof shall be governed by and construed in accordance
with the laws of the State of Maryland, without reference to principles of
conflicts of laws.

     13.2  INDEPENDENT CONTRACTORS.  The relationship of the parties hereto is
that of independent contractors. The parties hereto are not deemed to be agents,
partners or joint venturers of the others for any purpose as a result of this
Agreement or the transactions contemplated thereby.

     13.3  ASSIGNMENT.  Neither party may assign this Agreement without the
prior written consent of the other, which consent shall not be unreasonably
withheld; provided, however, either party may assign this Agreement in
connection with a transfer of all or substantially all of its assets relating to
the agreements, whether by sale, merger, operation of law or otherwise. This
Agreement shall be binding upon and inure to the benefit of the parties and
their permitted successors and assigns.

     13.4  NOTICES.  Any required notices hereunder shall be given in writing by
certified mail or overnight express delivery service at the address of each
party below, or to such other address as either party may indicate on its behalf
by written notice. Notice shall be deemed served when delivered or, if delivery
is not accomplished by reason or some fault of the addressee, when tendered.

     If to Scios:   Scios Inc.
                    2450 Bayshore Parkway
                    Mountain View, CA  94043
                    Attention: General Counsel
                    with a copy to:  Vice President, Business Development

     If to GenVec:  GenVec, Inc.
                    12111 Parklawn Drive
                    Rockville, MD  20852
                    Attention:  President
                    with a copy to:  Vice President, Corporate Development

     13.5  FORCE MAJEURE.  Neither party shall lose any rights hereunder or be
liable to the other party for damages or losses (except for payment obligations)
on account of failure of performance by the defaulting party if the failure is
occasioned by war, strike, fire, Act of God, earthquake, flood, lockout,
embargo, governmental acts or orders or restrictions, failure of suppliers, or
any other

                                      -19-

<PAGE>

reason where failure to perform is beyond the reasonable control and not caused
by the negligence, intentional conduct or misconduct of the nonperforming party
and the nonperforming party has exerted all reasonable efforts to avoid or
remedy such force majeure; provided, however, that in no event shall a party be
required to settle any labor dispute or disturbance.

     13.6  COMPLIANCE WITH LAWS.  Each party shall furnish to the other party
any information related to the subject matter of this Agreement requested or
required by that party during the term of this Agreement or any extensions
hereof to enable that party to comply with the requirements of any U.S. or
foreign federal, state and/or government agency.

     13.7  COVENANT NOT TO SUE.  During the term of this Agreement, Scios agrees
not to assert or enforce against GenVec or any GenVec sublicensee any
intellectual property right owned or controlled by Scios or its Affiliates which
GenVec or its sublicensees may infringe or practice in connection with the
development, manufacture, use, import, sale or other commercialization of any
Licensed Product.

     13.8  LIMITATION OF LIABILITY.  NEITHER PARTY SHALL BE LIABLE TO THE OTHER
FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES ARISING OUT OF
THE PERFORMANCE OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF
LIABILITY.

     13.9  ADVICE OF COUNSEL.  GenVec and Scios have each consulted counsel of
their choice regarding this Agreement, and each acknowledges and agrees that
this Agreement shall not be deemed to have been drafted by one party or another
and will be construed accordingly.

     13.10 FURTHER ASSURANCES.  At any time or from time to time on and after
the date of this Agreement, either party shall at the request of the other party
(i) deliver to the requesting party such records, data or other documents
consistent with the provisions of this Agreement, (ii) execute, and deliver or
cause to be delivered, all such consents, documents or further instruments of
assignment, transfer or license, and (iii) take or cause to be taken all such
actions, as the requesting party may reasonably deem necessary or desirable in
order for the requesting party to obtain the full benefits of this Agreement and
the transactions contemplated hereby.

     13.11 SEVERABILITY.  In the event that any provisions of this Agreement are
determined to be invalid or unenforceable by a court of competent jurisdiction,
the remainder of the Agreement shall remain in full force and effect without
said provision. The parties shall in good faith negotiate a substitute clause
for any provision declared invalid or unenforceable, which shall most nearly
approximate the intent of the parties in entering this Agreement; provided, if
the parties are unable to agree on such a substitute clause and the deletion of
the provision held invalid or unenforceable would produce material adverse
financial consequences for one party, such party shall have the right to
terminate the Agreement with one hundred eighty (180) days notice.

                                      -20-

<PAGE>

     13.12 WAIVER.  The failure of a party to enforce any provision of the
Agreement shall not be construed to be a waiver of the right of such party to
thereafter enforce that provision or any other provision or right.

     13.13 ENTIRE AGREEMENT; AMENDMENT.  This Agreement including, its Exhibits,
sets forth the entire agreement and understanding of the parties with respect to
the subject matter hereof, and supersedes all prior discussions, agreements and
writings in relating thereto including, without limitation, the Confidentiality
Agreement entered by the parties dated March 14, 1996. This Agreement may not be
altered, amended or modified in any way except by a writing signed by both
parties.

     13.14 COUNTERPARTS.  This Agreement may be executed in two counterparts,
each of which shall be deemed an original and which together shall constitute
one instrument.

          IN WITNESS WHEREOF, Scios and GenVec have executed this Agreement by
their respective duly authorized representatives.

SCIOS INC.                          GENVEC, INC.

By:                                   By:
   --------------------------            ----------------------------

Print Name:                           Print Name:
           ------------------                    --------------------

Title:                                Title:
      -----------------------               -------------------------

                                      -21-

<PAGE>

                                    EXHIBIT A

                           PATENT RIGHTS (SCIOS INC.)

                                         *
<PAGE>

                                    EXHIBIT B

                         SCIOS INC. BIOLOGICAL MATERIALS

                                         *
<PAGE>

                                                                       EXHIBIT C

                                WARRANT AGREEMENT

     This WARRANT AGREEMENT is entered into as of this 31st day of May, 1996, by
and between GENVEC, INC., a Delaware corporation with its principal place of
business at 12111 Parklawn Drive, Rockville, Maryland 20852 (the "Company") and
SCIOS INC., a Delaware corporation with its principal place of business at 2450
Bayshore Parkway, Mountain View, California 94043 (the "Holder").

     WHEREAS, the Company and the Holder have entered into a License Agreement,
dated as of the date hereof (the "License Agreement"), pursuant to which the
Holder has granted to the Company a license for the Patent Rights and Know-How
(as such terms are defined in the License Agreement) relating to vascular
endothelial growth factor ("VEGF") 121 and nucleic acid sequences encoding VEGF
121 and the Company and the Holder have agreed to cooperate to facilitate the
development of proprietary VEGF products; and

     WHEREAS, the company desires to grant to the Holder the rights set forth in
this Warrant Agreement as part of the consideration for the Holder entering into
the License Agreement;

     NOW, THEREFORE, in consideration of the mutual agreements, undertakings and
covenants set forth in this Warrant Agreement, and for other good and valuable
consideration, the receipt, sufficiency and adequacy of which are hereby
acknowledged, the parties, intending to be legally bound, agree as follows:

     1.   THE WARRANT.  The Company hereby agrees to issue and sell to the
Holder one million two hundred fifty thousand (1,250,000) shares (the "Warrant
Shares") , of the Company's common stock, par value $.01 per share ("Common
Stock"), at an exercise price of two and a quarter U.S. dollars ($2.25) per
share (the "Exercise Price"), subject to the vesting schedule described in
Section 2 and the other provisions of this Warrant Agreement and upon the terms
and conditions herein set forth. The Exercise Price and the number of Warrant
Shares purchasable upon exercise of this Warrant Agreement are subject to
adjustment from time to time as provided in Section 8 of this Warrant Agreement.

     2.   VESTING SCHEDULE.  The Holder's right to exercise this warrant
Agreement will vest in the following increments (the "Increments") upon the
occurrence of the specified event (collectively, the "Events"), with respect to
a Licensed Product (as defined in the License Agreement), or the specified date:
(a) twenty-five percent (25%) of the Warrant Shares upon the earlier of
demonstration of efficacy in a pre-clinical animal model of cardiac ischemia or
December 31, 1997; (b) twenty-five percent (25%) of the Warrant Shares upon the
earlier of completion of pre-clinical toxicology in support of an
investigational new drug application ("IND") filing or March 31, 1998; (c)
twenty-five percent (25%) of the Warrant Shares upon the earlier of initiation
of a Phase I or a Phase I/II clinical trial or June 30, 1998; and (d)
twenty-five percent (25%) of the Warrant Shares upon the earlier of

<PAGE>

completion of a Phase I or a Phase I/II clinical trial or June 30, 1999. If
either the Company or the Holder provides notice that it intends to terminate
the License Agreement (and does not voluntarily revoke that notice of
termination by written notice to the other party), pursuant to Section 12 of the
License Agreement ("Cancels the License Agreement"), or the License Agreement
otherwise terminates prior to the vesting in full of this Warrant Agreement
pursuant to this Section, the then unvested Increments will not vest and, as of
the date of such termination notice or termination, this Warrant Agreement will
be null and void with respect to such unvested Increments (notwithstanding any
notice period or period staying termination of the License Agreement under
Section 12 of the License Agreement; PROVIDED, HOWEVER, that if the License
Agreement is reinstated voluntarily by both parties or through arbitration
pursuant to Section 12 of the License Agreement, the Warrant Agreement will
similarly be reinstated, except that the Increments that were unvested as of the
date of the termination notice or termination will vest upon the earlier of the
respective Events or such respective dates as are reasonably agreed to by the
parties or determined as a part of the arbitration). If the Company or the
Holder Cancels the License Agreement or the License Agreement otherwise
terminates after any Increment vests, this Warrant Agreement will continue to be
exercisable, to the extent of any then unexercised portion of the vested
Increments, until the Expiration Date (as defined in Section 3 of this Warrant
Agreement).

     3.   EXPIRATION DATE.  This Warrant Agreement, and the Holder's right to
purchase any of the Warrant Shares, will expire and cease to be of force and
effect at 5:00 p.m. Eastern Standard Time on the fifth (5th) anniversary of the
date of this Warrant Agreement (the "Expiration Date"); PROVIDED, HOWEVER, that
if the Company has not completed an initial public offering of Common Stock (the
"IPO") within two (2) years from the date of this Warrant Agreement, the
"Expiration Date" will be the fifth (5th) anniversary of the effective date of
the IPO; PROVIDED FURTHER, that, notwithstanding any other provision of this
Section or this Warrant Agreement, the "Expiration Date" will not be any later
than the tenth (10th) anniversary of the date of this Warrant Agreement.

     4. EXERCISE OF THIS WARRANT AGREEMENT. The Holder may exercise this
Warrant Agreement, to the extent of any then unexercised portion of the vested
Increments, at any time prior to the Expiration Date, in whole or in part, (i)
for amounts not less than one hundred thousand (100,000) Warrant Shares subject
to this Warrant Agreement, as adjusted from time to time as provided in Section
8 of this warrant Agreement, or (ii) as a one-time exercise under this Warrant
Agreement, for any unexercised portion of the vested Increments, by: (a) the
surrender of this Warrant Agreement, With the Exercise Form attached hereto as
Annex A properly completed and executed, at the principal office of the Company
at 12111 Parklawn Drive, Rockville, Maryland 20852 or at such other office of
the Company as the Company may designate by notice in writing to the holder of
this Warrant Agreement, and (b) the delivery of a certified check, bank draft or
wire transfer of immediately available funds, payable to the order of GenVec,
Inc., in an amount equal to the then aggregate purchase price for the Warrant
Shares being purchased upon such exercise. Upon receipt thereof by the Company
on a business day, the Holder will be deemed to be the holder of record of the
Warrant Shares issuable upon such exercise as of the close of business on the
date of such receipt by the Company, and the Company will promptly execute or
cause to be executed and delivered to the Holder, a certificate or certificates
representing the aggregate number of Warrant Shares specified in the Exercise
Form. If this Warrant Agreement is exercised only in part and has

                                      -2-
<PAGE>

not expired, the Company will, at the time of delivery of said stock certificate
or certificates, deliver to the Holder a new Warrant Agreement of like tenor
evidencing the right of the Holder to purchase the remaining Warrant Shares then
covered by this Warrant Agreement. The Company will pay all expenses, taxes
(excluding any income taxes incurred by the Holder) and other charges payable in
connection with the preparation, execution and delivery of stock certificates
pursuant to this Section.

     5. REPRESENTATIONS OF THE COMPANY. The Company hereby represents and
warrants to the Holder as follows:

          (a) The Company is a corporation duly organized, validly existing and
in good standing under the laws of the State of Delaware.

          (b) This Warrant Agreement has been duly authorized by all necessary
corporate action on the part of the Company, has been duly executed by a duly
authorized officer of the Company, and constitutes a valid and binding
obligation of the Company.

          (c) Neither the execution and delivery of this Warrant Agreement nor
the consummation of the transactions contemplated hereby will violate or result
in any violation of or be in conflict with or constitute a default under any
term of the charter or bylaws of the Company or of any agreement, instrument,
judgment, decree, order, statute, rule or governmental regulation applicable to
the Company.

          (d) Upon exercise of this Warrant Agreement and payment of the then
aggregate purchase price by the Holder, the Warrant Shares deliverable hereunder
will be duly issued, fully paid and nonassessable shares and free from all
taxes, liens and charges with respect to the issuance thereof.

     6. REPRESENTATIONS OF THE HOLDER. The Holder hereby represents and
warrants to the Company as follows:

          (a) The Holder is a corporation duly organized, validly existing and
in good standing under the laws of Delaware.

          (b) The Holder is acquiring this Warrant Agreement, and will acquire
the Warrant Shares issuable upon exercise of this Warrant Agreement, for
investment for its own account and not with a view to, or for resale in
connection with, any distribution of this Warrant Agreement or the Warrant
Shares issuable upon exercise of this warrant Agreement. The Holder understands
that neither this Warrant Agreement nor the Warrant Shares issuable upon
exercise of this Warrant Agreement have been registered under the Securities Act
of 1933, as amended (the "Securities Act") , or under any state securities laws,
and, as a result thereof, are subject to substantial restrictions on transfer.
The Holder acknowledges that this Warrant Agreement and the shares issuable upon
exercise of this Warrant Agreement must be held indefinitely, unless
subsequently registered under the Securities Act and any applicable state
securities laws or unless exemptions from registration under the Securities Act
and such laws are available.

                                      -3-
<PAGE>

          (c) The Holder is an "accredited investor," as that term is defined in
Rule 501 under the Securities Act.

          (d) The Holder is either (i) not an "Investment Company," as that term
is defined in the Investment Company Act of 1940, or (ii) excluded from the
definition of an Investment Company under Section 3(c)(1) of the Investment
Company Act of 1940.

     7.   SURVIVAL OF REPRESENTATIONS.  The representations and warranties made
in Sections 5 and 6 of this Warrant Agreement will survive the date of this
Warrant Agreement and will expire upon the earliest of (a) the Expiration Date,
(b) if the Company Cancels the License Agreement or the License Agreement
otherwise terminates before any Increment vests, the date of the termination of
the License Agreement, (c) if the Company Cancels the License Agreement or the
License Agreement otherwise terminates after any Increment vests, the exercise
of the entire unexercised portion of the vested Increments, or (d) the exercise
of this Warrant Agreement for all of the remaining Warrant Shares purchasable
upon exercise of this Warrant Agreement.

     8.   CERTAIN ADJUSTMENTS.  The Exercise Price at which Warrant Shares may
be purchased and the number of Warrant Shares to be purchased upon exercise of
this Warrant Agreement are subject to change or adjustment as follows:

          (a) STOCK DIVIDENDS, DISTRIBUTIONS, SUBDIVISIONS, COMBINATIONS OR
RECLASSIFICATIONS.  In case the Company (i) pays a dividend in shares of Common
Stock or makes a distribution in shares of Common Stock, (ii) subdivides its
outstanding shares of Common Stock, (iii) combines its outstanding shares of
Common Stock into a smaller number of shares of Common Stock or (iv) issues, by
reclassification of its shares of Common Stock, other securities of the Company
(including any such reclassification in connection with a consolidation or
merger in which the Company is the surviving corporation), the number of Warrant
Shares purchasable upon exercise of this Warrant Agreement will be adjusted so
that the Holder will be entitled to receive the kind and number of Warrant
Shares or other securities of the Company which it would have owned or have been
entitled to receive after the happening of any of the events described above, if
this Warrant Agreement had been exercised immediately prior to the happening of
such event or any record date with respect thereto. Whenever the number of
Warrant Shares purchasable upon the exercise of this Warrant Agreement is
adjusted, as herein provided, the Exercise Price payable upon the exercise of
this Warrant Agreement will be adjusted by multiplying such Exercise Price
immediately prior to such adjustment by a fraction, of which the numerator will
be the number of Warrant Shares purchasable upon the exercise of this Warrant
Agreement immediately prior to such adjustment, and of which the denominator
will be the number of Warrant Shares purchasable immediately thereafter. An
adjustment made pursuant to this Subsection 8(a) will become effective
immediately after the effective date of such event retroactive to the record
date, if any, for such event. No adjustment in the number of Warrant Shares
purchasable hereunder will be required unless such adjustment would require an
increase or decrease of at least one percent (it) in the number of Warrant
Shares purchasable upon the exercise of this Warrant Agreement; PROVIDED,
HOWEVER, that any adjustments which by reason of this restriction are not
required to be made will be carried forward and taken into

                                      -4-
<PAGE>

account in any subsequent adjustment. All calculations will be made to the
nearest one-thousandth of a share.

          (b) PRESERVATION OF PURCHASE RIGHTS UPON MERGER, CONSOLIDATION, ETC.
In case of any consolidation of the Company with or merger of the Company into
another corporation or other entity or in case of any sale, transfer or lease to
another corporation or other entity of all or substantially all the property of
the Company, the Company or such successor or purchasing corporation or other
entity, as the case may be, will, at its option, (i) if any Increment has
vested, pay the Holder an amount in cash equal to the number of Warrant Shares
then exercisable pursuant to this Warrant Agreement multiplied by the difference
between (A) the value of the aggregate consideration in the consolidation,
merger, sale, transfer or lease divided by the number of fully-diluted shares of
Common Stock then outstanding and (B) the then current Exercise Price, (ii)
execute with the Holder an agreement that the Holder will have the right
thereafter, upon vesting of any increment and payment of the Exercise Price in
effect immediately prior to such action, to purchase upon exercise of this
Warrant Agreement the kind and amount of shares and other securities and
property which the Holder would have owned or have been entitled to receive
after the happening of such consolidation, merger, sale, transfer or lease had
this Warrant Agreement been exercised immediately prior to such action, or (iii)
combine its options under (i) and (ii) of this Subsection 8 (b); PROVIDED,
HOWEVER, that no adjustment in respect of cash dividends, interest or other
income on or from such shares or other securities and property will be made
during the term of this Warrant Agreement or upon the exercise of this Warrant
Agreement. Any agreement executed under Subsection 8(b) (ii) or (iii) will
provide for adjustments, which will be as nearly equivalent as may be
practicable to the adjustments provided for in this Section 8. The provisions of
this Subsection 8(b) will similarly apply to successive consolidations, mergers,
sales, transfers or leases.

          (c) NO ADJUSTMENT FOR CASH DIVIDENDS.  No adjustment in respect of any
cash dividends will be made during the term of this Warrant Agreement or upon
the exercise of this Warrant Agreement.

     9.   FRACTIONAL SHARES.  Fractional shares will not be issued upon the
exercise of this Warrant Agreement, but in any case where the Holder would,
except for the provisions of this Section, be entitled under the terms of this
Warrant Agreement to receive a fractional share upon the exercise of this
Warrant Agreement, the Company will, upon the exercise of this Warrant Agreement
for the largest number of whole shares then called for, pay a sum in cash equal
to the excess of the market value of such fractional share (determined in such
reasonable manner as may be prescribed by the Board of Directors of the Company
in its discretion) over the proportional part of the per share purchase price
represented by such fractional share.

     10.  TAXES.  The Company covenants and agrees that it will pay when due and
payable any federal taxes and any taxes imposed by the State of Delaware, other
than income taxes incurred by the Holder, in respect of the issue of this
Warrant Agreement, or any Warrant Shares or certificates therefor upon the
exercise of this Warrant Agreement pursuant to the provisions of this Warrant
Agreement.

                                      -5-
<PAGE>

     11. NOTICE OF CERTAIN EVENTS. In case at any time the Company:

          (a) Cancels the License Agreement prior to the vesting in full of this
Warrant Agreement;

          (b) proposes, by resolution of its Board of Directors, a stock
dividend, distribution, subdivision, combination or reclassification of the
shares of capital stock of the Company for which this Warrant Agreement is
exercisable; or

          (c) proposes, by resolution of its Board of Directors, any capital
reorganization or any reclassification or change of capital stock that affects
the Warrant Shares of the Company or any consolidation, merger or sale of
properties and assets of the type described in Section 8 of this Warrant
Agreement;

then, and in each of said cases, the Company will cause notice thereof to be
delivered promptly to the Holder; PROVIDED, HOWEVER, that the Company need not
deliver any separate notice pursuant to Subsection 11(a) if such notice is
provided in accordance with the License Agreement and need not deliver any
notice pursuant to Subsection 11(b) until after any Increment has vested and
unless there exists a then unexercised portion of the vested Increments;
PROVIDED further, that the Company will deliver any notice pursuant to
Subsection 11(c) at least ten (10) days prior to the effective date of the
proposed event.

     12. RESERVATION OF SHARES. The Company will at all times reserve and keep
available out of its authorized but unissued stock, for the purpose of effecting
the exercise of this warrant Agreement, such number of its duly authorized
shares of capital stock for which this Warrant Agreement is exercisable, and the
appropriate number of shares of any stock into which such stock is convertible,
as will from time to time be sufficient to effect the exercise of this Warrant
Agreement.

     13.  NO RIGHTS AS SHAREHOLDER; LIMITATION OF LIABILITY.  This Warrant
Agreement, as distinct from the shares for which this Warrant Agreement is
exercisable, will not entitle the Holder to any of the rights of a shareholder
of the Company. No provision of this Warrant Agreement, in the absence of
affirmative action by the Holder to purchase the Warrant Shares, and no mere
enumeration herein of the rights or privileges of the Holder, will give rise to
any liability of the Holder for the purchase price or as a shareholder of the
Company, whether such liability is asserted by the Company or by creditors of
the Company.

     14.  TRANSFER RESTRICTIONS.

          (a) SECURITIES LAWS.  NEITHER THIS WARRANT AGREEMENT NOR THE
SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE. NEITHER
THIS WARRANT AGREEMENT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF NOR ANY
INTEREST OR PARTICIPATION HEREIN OR THEREIN MAY BE SOLD, ASSIGNED, PLEDGED,
HYPOTHECATED, ENCUMBERED OR IN

                                      -6-
<PAGE>

ANY OTHER MANNER TRANSFERRED OR DISPOSED OF EXCEPT IN COMPLIANCE WITH THE
SECURITIES ACT OF 1933, AS AMENDED, THE SECURITIES LAWS OF EACH RELEVANT STATE,
AND THE TERMS AND CONDITIONS HEREOF. EACH OF THE HOLDER OF THIS WARRANT
AGREEMENT AND THE HOLDER OF THE SECURITIES ISSUABLE UPON EXERCISE HEREOF IS
SUBJECT TO THE RESTRICTIONS HEREIN SET FORTH.

          (b) STOCK CERTIFICATE LEGEND.  Each certificate for shares issued upon
exercise of this Warrant Agreement will bear the following legend:

          "The shares represented by this certificate have been acquired for
          investment and have not been registered under the Securities Act of
          1933, as amended, or the securities laws of any State. Neither the
          shares nor any interest or participation in the shares may be sold,
          assigned, pledged, hypothecated, encumbered or in any other manner
          transferred or disposed of in the absence of such registration or
          exemption therefrom under such Act or such laws and an opinion (which
          will be in form and substance satisfactory to the Company) of counsel
          satisfactory to the Company that such registration is not required."

          (c) GENERAL RESTRICTIONS.  The Holder may not transfer or assign this
Warrant Agreement unless it is transferred or assigned to the purchaser of all
of the outstanding capital stock or all or substantially all of the assets,
including every right and interest the Holder may have in the Patent Rights and
Know-How, of the Holder. The Company may deem and treat the person in whose name
this Warrant Agreement is registered as the holder and owner hereof
(notwithstanding any notations of ownership or writing hereon made by anyone
other than the Company) for all purposes and will not be affected by any notice
to the contrary, until presentation of this Warrant Agreement to the Company for
registration of transfer consistent with this Section. The holder of this
Warrant Agreement further agrees that prior to any transfer of this Warrant
Agreement, consistent with this Section, or any transfer of the shares issued
upon exercise hereof, such holder will give written notice to the Company,
together with a copy of the opinion of such holder's counsel as to the
availability of exemption from registration under all applicable securities laws
in connection with any such transfer (which opinion will be reasonably
satisfactory to counsel for the Company).

     15.  LOCK-UP. In connection with any public offering of shares of Common
Stock, the Holder agrees to enter into a written agreement-with the managing
underwriters, if the managing underwriters demand or request such an agreement
from the Holder and from all holders (the "Other Holders") of more shares of
Common Stock, or of shares of preferred stock convertible into more shares of
Common Stock, than the number of shares of Common Stock owned by the Holder
(regardless of whether the managing underwriters obtain such an agreement from
any of the Other Holders), in such form and containing such provisions as are
required by the managing underwriters (except that such provisions will not be
less favorable to the Holder than the provisions of any agreements entered into
by the managing underwriters with the Other Holders) to preclude the Holder from
directly or indirectly offering to sell, contracting to sell or otherwise
disposing of any shares of Common Stock, any options or warrants to purchase
shares of Common Stock, or any

                                      -7-
<PAGE>

securities convertible into or exchangeable for shares of Common Stock for a
period of time not to exceed one hundred eighty (180) days after the effective
date of the registration statement for the public offering.

     16.  REGISTRATION RIGHTS.

          (a) PIGGYBACK REGISTRATION RIGHTS.

              (i) If the Company plans to file a registration statement under
the Securities Act on a Form S-3 to register any shares of Common Stock for sale
by it or any of its stockholders (the "Piggyback Registration Statement")
(except in connection with any stock option plan, stock purchase plan, savings
or similar plan), the Company shall provide the Holder with the right to
include- Warrant Shares on the Piggyback Registration Statement (the "Piggyback
Right") , if the Holder is the stockholder of record of any Warrant Shares at
such time or has the vested right to acquire any Warrant Shares pursuant to this
Warrant Agreement at such time, by providing the Holder with at least thirty
(30) days prior written notice thereof. At the written request of the Holder,
given within twenty (20) days after the receipt of such notice, the Company will
use its best efforts to cause all of the Warrant Shares for which registration
shall have been requested to be included in the Piggyback Registration
Statement. The Company shall provide the Holder with four Piggyback Rights to
register Warrant Shares under this provision.

              (ii) In the event that the proposed offering is an offering by the
Company that is, in whole or in part, an underwritten public offering of shares
of Common Stock, and the managing underwriters determine and advise in writing
that the inclusion of the Warrant Shares proposed to be included in the
underwritten public offering and any other issued and outstanding shares of
Common Stock or other securities proposed to be included therein by the security
holders of the Company (the "Other Shares") would interfere with the successful
marketing (including pricing) of the shares, the number of the Holder's Warrant
Shares and the Other Shares to be included in such underwritten public offering
shall be reduced first, pro rata among the Holder and the holders of Other
Shares (other than the holders of shares of the Company's Class A Convertible
Preferred Stock, par value $.01 per share (the "Class A Preferred Stock"), the
Company's Class B Convertible Preferred Stock, par value $.01 per share (the
"Class B Preferred Stock"), the shares of Common Stock that have been issued
upon conversion of the Class A Preferred Stock and the Class B Preferred Stock,
and any shares of Common Stock or other securities issued in respect of any such
securities upon any stock split, stock dividend, recapitalization, merger,
consolidation or similar event ("Original Registration Stock")); second, if
necessary, pro rata among the holders of Original Registration Stock, based upon
the number of shares requested by holders thereof to be registered in such
underwritten public offering; and lastly, if necessary, among the Company's
shares requested by the Company to be registered.

          (b) DEMAND REGISTRATION RIGHT.  Beginning after June 1, 1999, the
Holder shall have one right to demand, by providing written notice to the
Company (the "Demand Registration Right"), that the Company file a registration
statement on Form S-3 to register Warrant Shares for resale by the Holder in an
offering that is not underwritten (the "Registration Statement").  The

                                      -8-
<PAGE>

Company agrees to use its best efforts (i) to file the Registration Statement
with the Securities and Exchange Commission ("SEC") within one hundred eighty
(180) days of receipt of the Holder's notice of its exercise of the Demand
Registration Right, (ii) to obtain the effectiveness of the Registration
Statement and (iii) to keep such Registration Statement effective for a period
of sixty (60) days after its effectiveness. The Holder agrees that it will cease
making offers and sales under the Registration Statement upon the giving of any
notice (the "Notice") by the Company that the Registration Statement must be
amended or supplemented. If the Company shall give any such notice, the Company
will agree to keep the Registration Statement effective after it is amended or
supplemented for such period of time equal to the sum of (i) the number of days
beginning with the date of the Notice to the date the Holder has received an
effective amended prospectus or a supplemented prospectus plus (y) sixty (60)
less the number of days the Registration Statement was useable by the Holder
prior to the Notice. If the Registration Statement is not filed with the SEC by
the one hundred eightieth (180th) day after the Company's receipt of the
Holder's notice of its exercise of the Demand Registration Right, the Holder
shall have the right to a Cashless Exercise (as defined in Exhibit A attached
hereto) of the Warrant Shares provided that the then current Market Price (as
defined in Exhibit A attached hereto) exceeds the then current Exercise Price.

          (c) Whenever the Company is required to register any of the Holder's
Warrant Shares pursuant to any of the provisions of this Section 16, the Company
shall also be obligated to do the following:

              (i) Furnish to the Holder such copies of preliminary and final
prospectuses and such other documents as the Holder may reasonably request to
facilitate the public offering of the Holder's Warrant Shares;

              (ii) Use its best efforts to register or qualify the warrant
Shares covered by said registration statement under the securities or Blue Sky
laws of such jurisdictions as the Holder may reasonably request; PROVIDED,
however, that the Company shall not be required to qualify generally to do
business in any jurisdiction where it is not then so qualified, take any action
that would subject it to general service of process in any such jurisdiction
where it is not then so subject or subject the Company to any tax in any such
jurisdiction where it is not then so subject;

              (iii) Permit the Holder or its counsel or other representatives,
at the Holder's expense, to inspect and copy such corporate documents and
records as may reasonably be requested by them; and

              (iv) Furnish to the Holder a copy of all documents filed and all
correspondence to or from the Securities and Exchange Commission in connection
with any such offering.

          (d) The Holder shall bear all of the fees and expenses of its counsel
in connection with the registration statement and the offering. The Holder shall
bear all other expenses in connection with the preparation and filing of any
Registration Statement and its pro rata share of all other expenses in
connection with the preparation and filing of any Piggyback Registration
Statement

                                      -9-
<PAGE>

under this Section 16, any registration or qualification under the securities or
Blue Sky laws of states in which the offering will be made under either such
registration statement and any filing fee of the National Association of
Securities Dealers, Inc. relating to such offering and of any underwriters' or
brokers' commission.

          (e) In connection with any public underwritten offering, the Company
and the Holder shall enter into a written agreement with the managing
underwriters in such form and containing such provisions as are customary in the
securities business for such an arrangement between such managing underwriters
and companies of the Company's size and investment stature, including
indemnification.

     17.  MISCELLANEOUS.

          (a) AMENDMENTS AND WAIVERS.  This Warrant Agreement and any provision
hereof may be changed, waived, discharged or terminated only by an instrument in
writing signed by the party (or any predecessor in interest thereof) against
which enforcement of the same is sought.

          (b) SUCCESSORS AND ASSIGNS. This Warrant Agreement will be binding
upon and inure to the benefit of the successors and assigns of the Company and
the heirs and permitted registered assigns and transferees of the Holder.

          (c) LOSS, THEFT, DESTRUCTION OR MUTILATION.  Upon receipt by the
Company of evidence reasonably satisfactory to it that this Warrant Agreement
has been lost, stolen, destroyed or mutilated, and in the case of any lost,
stolen or destroyed Warrant Agreement, a bond of indemnity reasonably
satisfactory to the Company, or in the case of a mutilated Warrant Agreement,
upon surrender and cancellation hereof, the Company will execute and deliver in
the name of the registered holder of this Warrant Agreement, in exchange and
substitution for the Warrant Agreement so lost, stolen, destroyed or mutilated,
a new Warrant Agreement of like tenor with appropriate insertions and
variations.

          (d) LAW GOVERNING.  This Warrant Agreement will be governed by, and
construed and enforced in accordance with, the internal laws of the State of
Delaware.

          (e) ENTIRE AGREEMENT.  This Warrant Agreement and the attached annex
constitute the full and entire understanding and agreement among the parties
with regard to the subject of this Warrant Agreement and the attached annex, and
supersede all prior agreements, understandings, inducements or conditions,
express or implied, oral or written, with respect to the subject of this Warrant
Agreement and the attached annex.

          (f) NOTICES. Unless otherwise provided, all notices, requests, demands
and other communications required or permitted under this Warrant Agreement will
be in writing and will be deemed to have been duly made and received: (i) upon
personal delivery or confirmed facsimile to the party to be notified; (ii) three
(3) business days after deposit with the United States Post Office, by
registered or certified mail or by first class mail, postage prepaid, addressed
as set forth below; or

                                     -10-
<PAGE>

(iii) one (1) business day after deposit with Federal Express or another
reputable overnight courier (for next business day delivery), shipping prepaid,
addressed as set forth below:

               (i)  If to the Company, then to:

                    GenVec, Inc.
                    12111 Parklawn Drive
                    Rockville, MD 20852

                    ATTN: Chief Financial Officer

                    with a copy to:

                    ATTN: Vice President -- Business Development

               (ii) If to the Holder, then to:

                    Scios Inc.
                    2450 Bayshore Parkway
                    Mountain View, CA 94043

                    ATTN: General Counsel

                    with a copy to:

                    Attn: Vice President -- Business Development

Either party may change the address to which communications are to be sent by
giving five (5) business days, advance notice of such change of address to the
other party in conformity with the provisions of this Section.

          (g) HEADINGS. The headings in this Warrant Agreement are for purposes
of reference only and will not affect the meaning or construction or any of the
provisions hereof.

          (h) EXECUTION; COUNTERPARTS.  This Warrant Agreement may be executed
in any number of counterparts, each of which will be deemed to be an original as
against any party whose signature appears on such counterpart, and all of which
will together constitute one and the same instrument. This Warrant Agreement
will become binding when one or more counterparts of this warrant Agreement,
individually or taken together, bear the signatures of all of the parties to
this Warrant Agreement and the seal of the Company.

                                     -11-
<PAGE>

     IN WITNESS WHEREOF, the parties have caused this warrant Agreement to be
duly executed and delivered as of the day and year first written above.

                              SCIOS INC.

                              By:
                                    -----------------------------------
                                      Name:
                                     Title:

                              GENVEC, INC.

                              By:
                                    -----------------------------------
                                    Thomas W. D'Alonzo
                                    President

Attest:

---------------------------
Charles A. Reinhart III
Secretary

[Corporate Seal]

                                     -12-
<PAGE>

                                                                         ANNEX A

                                  EXERCISE FORM

                     TO BE EXECUTED BY THE REGISTERED HOLDER
                  TO EXERCISE THE ATTACHED WARRANT AGREEMENT OF

                                  GENVEC, INC.

     The undersigned, the record holder of the attached original, executed
Warrant Agreement (the "Warrant Agreement") , pursuant to the provisions of the
Warrant Agreement, hereby irrevocably elects to exercise the right, represented
by the Warrant Agreement, to purchase Warrant Shares (as defined
in the Warrant Agreement) covered by the Warrant Agreement, and herewith tenders
payment in full therefor at the price per share provided by the Warrant
Agreement.

                              ------------------------------------

                              By:
                                    -----------------------------------
                                      Name:
                                     Title:

                         Address:
                                    -----------------------------------

                                    -----------------------------------

Dated:               ,
      --------------- -----

                                     -13-

<PAGE>

                                                                       EXHIBIT D

                   CLASS D PREFERRED STOCK PURCHASE AGREEMENT

     THIS AGREEMENT is entered into as of the 31st day of May 1996, by and
between GENVEC, INC., a Delaware corporation with its principal place of
business at 12111 Parklawn Drive, Rockville, Maryland 20852 (the "Company"), and
SCIOS INC., a Delaware corporation with its principal place of business at 2450
Bayshore Parkway, Mountain View, California 94043 (the "Investor"), with
reference to the following recitals:

     WHEREAS, the Company was incorporated on December 7, 1992, under the laws
of the State of Delaware;

     WHEREAS, the Company and the Investor have entered into a License
Agreement, dated as of the date hereof (the "License Agreement"), pursuant to
which the Investor has granted to the Company a license for the Patent Rights
and Know-How (as such terms are defined in the License Agreement) relating to
vascular endothelial growth factor ("VEGF") 121 and nucleic acid sequences
encoding VEGF 121 and the Company and the Investor have agreed to cooperate to
facilitate the development of proprietary VEGF products;

     WHEREAS, the Company and the Investor have entered into a Warrant
Agreement, dated as of the date hereof (the "Warrant Agreement"), pursuant to
which the Investor has the right to acquire, subject to vesting and other
restrictions described in the Warrant Agreement, shares of the Company's common
stock, par value $.01 per share ("Common Stock"); and

     WHEREAS, the Investor desires to purchase certain of the shares of the
capital stock of the Company on the terms hereinafter set forth.

     NOW, THEREFORE, in consideration of the mutual agreements, undertakings and
covenants set forth in this Agreement, and for other good and valuable
consideration, the receipt, sufficiency and adequacy of which are hereby
acknowledged, the parties, intending to be legally bound, agree as follows:

     1.   TERMS OF SALE.  The Company will issue and sell to the Investor, and
the Investor will purchase from the Company, 571,429 shares of the Company's
Class D Convertible Preferred Stock, par value $.01 per share (the "Shares") for
an aggregate purchase price of one million U.S. dollars and seventy-five cents
($1,000,000.75) as follows:

          (a) On or before the third (3)rd) business day after the date hereof,
the Investor will deliver to the Company a non-refundable deposit in the amount
of three hundred fifty thousand U.S. dollars ($350,000) by wire transfer of
immediately available funds; and

<PAGE>

          (b) On or before July 2, 1996, the Investor will deliver to the
Company a certified bank check, payable to the order of the Company, or a wire
transfer of immediately available funds in an amount of six hundred fifty
thousand U.S. dollars and seventy-five cents ($650,000.75) in payment for the
Shares. Upon receipt of such payment by the Company on a business day, the
Investor will be deemed to be the holder of record of the Shares and the Company
will promptly execute a certificate evidencing issuance to the Investor of the
appropriate number of fully-paid and nonassessable Shares.

     2.   REPRESENTATIONS AND WARRANTIES OF THE COMPANY.  The Company hereby
represents and warrants that:

          (a) The Company is a corporation duly organized, validly existing and
in good standing under the laws of the State of Delaware.

          (b) The Company has all necessary corporate power to enter into this
Agreement, to issue and deliver the Shares hereunder and to carry out all of the
transactions contemplated hereby. The execution, delivery and performance of
this Agreement by the Company and the consummation of the transactions
contemplated hereby, including, without limitation, the issuance of the Shares,
have been duly authorized by all requisite corporate action on the part of the
Company. This Agreement constitutes a valid and binding instrument of the
Company, enforceable in accordance with its terms, subject, as to enforcement,
to bankruptcy, insolvency, reorganization and other laws of general
applicability relating to or affecting creditors' rights and to general equity
principles.

          (c) As of the date of this Agreement, the Company's authorized capital
stock consists of (i) 51,305,095 shares of Common Stock, 3,747,629 of which are
outstanding; (ii) 1,334,000 shares of Class A Convertible Preferred Stock, par
value $.01 per share, 1,334,000 of which are outstanding; (iii) 11,800,468
shares of Class B Convertible Preferred Stock, par value $.01 per share,
11,320,314 of which are outstanding; (iv) 21,065,000 shares of Class C
Convertible Preferred Stock, par value $.01 per share, 21,065,000 of which are
outstanding; and (v) 2,000,000 shares of Class D Convertible Preferred Stock,
par value $.01 per share, none of which are outstanding. There are no treasury
shares held by the Company. All outstanding shares of capital stock are, and the
Shares, when issued in accordance with or as contemplated by the terms of this
Agreement, will be validly issued and outstanding, fully paid and nonassessable.
The shares of Common Stock issuable upon conversion of the Shares are duly and
validly authorized and reserved for issuance. Each share of Class D Convertible
Preferred Stock is convertible into a share or shares of Common Stock, at the
rate, and otherwise has the designations, preferences, limitations and rights,
provided for in Article NINTH, attached hereto as EXHIBIT A, of the Company's
Certificate of Incorporation as duly approved by the
Company's stockholders.

                                      -2-
<PAGE>

          (d) The Company has made available to the Investors complete and
correct copies of the Company's unaudited financial statements, attached hereto
as Exhibit B, for the four-month period ended April 30, 1996. The unaudited
financial statements have been prepared in a manner consistent with generally
accepted accounting principles, subject to normal year-end audit adjustments and
except that the unaudited financial statements may not contain all footnotes
required by generally accepted accounting principles. The financial statements
reflect all adjustments which are, in the opinion of management, necessary to a
fair statement of the results of the Company for the period presented.

          (e) The Company has no liabilities, except: (i) as disclosed or
reflected in the financial statements attached hereto as EXHIBIT B; or (ii)
liabilities not in excess of two hundred fifty thousand U.S. dollars ($250,000).

          (f) To the Company's knowledge, there are neither any pending or
threatened suits, legal proceedings, claims or governmental investigations
against or with respect to the Company or its properties or assets nor any basis
for any such suit, legal proceedings, claim or governmental investigation.

     3.   REPRESENTATIONS AND WARRANTIES OF THE INVESTOR.  The Investor hereby
represents and warrants that:

          (a) The Investor is acquiring the Shares for purposes of investment
for its own account and not with a view to, or for resale in connection with,
the distribution thereof, as those terms are used in the Securities Act of 1933,
as amended (the "Securities Act"), and the rules and regulations promulgated
thereunder. The Investor has been advised and acknowledges that it will not be
able to dispose of the Shares, or any interest therein, without first complying
with the relevant provisions of the Securities Act and any applicable state
securities laws. The Investor also understands that the provisions of Rule 144
promulgated under the Securities Act, permitting routine sales of securities of
certain issuers subject to the terms and conditions thereof, are not currently
available to it with respect to the Shares. The Investor acknowledges that the
Company is under no obligation to register the Shares or to take any action to
assist the Investor in complying with terms and conditions of any exemption that
might be available under the Securities Act or any state securities laws with
respect to sales of the Shares by the Investor in the future.

          (b) The Investor is an "accredited investor," as that term is defined
in Rule 501 promulgated under the Securities Act.

          (c) The Investor is either (1) not an "Investment Company," as that
term is defined in the Investment Company Act of 1940, as amended (the
"Investment Company Act") or (ii) excluded from the definition of an Investment
Company under Section 3)(c)(1) of the Investment Company Act.

          (d) The Investor acknowledges that the representations, agreements and
acknowledgements set forth above are being given by the Investor with the
understanding that they

                                      -3-
<PAGE>

will be relied on by the Company and its Board of Directors to claim the
availability of the exemption from the registration provisions of the Securities
Act contained in Regulation D promulgated thereunder.

     4. COVENANTS OF THE COMPANY. The Company hereby covenants that, so long
as (i) the Investor owns any shares of the Company's Class D Convertible
Preferred Stock or shares of Common Stock into which such shares of Class D
Convertible Preferred Stock are convertible and (ii) the Company has not
consummated an underwritten public offering of Common Stock pursuant to one or
more registration statements filed under the Securities Act (or any successor
statute), which yields gross proceeds to the Company of at least $15,000,000 and
under which the offering price to the public is equal to at least $1.50 per
share (adjusted for any stock splits, stock dividends, recapitalizations,
mergers, consolidations or similar events occurring after the date hereof), the
Company shall furnish to the Investor the following financial statements,
reports and other documents, such annual financial statements to be prepared in
accordance with generally accepted accounting principles consistently applied
(except as may be noted therein) and such interim financial statements to be
prepared in a manner consistent with the annual financial statements and
consistent with generally accepted accounting principles (subject to normal
year-end audit adjustments and the omission of footnotes required by generally
accepted accounting principles), certified by the Company's chief executive or
financial officer:

          (a) As soon as available, and in any event within 120 days after the
end of each fiscal year of the Company, a balance sheet of the Company as of the
end of such fiscal year and related statements of operations, stockholders'
equity and cash flows for such fiscal year, all in reasonable detail and setting
forth in comparative form the figures as of the end of and for the previous
fiscal year, which financial statements shall have been audited, and shall be
accompanied by an opinion addressed to the Company from independent auditors.

          (b) As soon as available, and in any event within 45 days after the
end of each fiscal quarter of the Company, an unaudited balance sheet and
unaudited statements of operations and cash flows.

     5. COVENANTS OF THE INVESTOR.

          (a) The Investor agrees to hold the Shares subject to all applicable
provisions of the Securities Act, applicable state securities laws, the
Certificate of Incorporation and the Amended and Restated By-laws of the Company
and this Agreement. The Investor shall give the Company prompt written notice of
any such proposed disposition and shall not proceed with any such proposed
disposition unless a registration under the Securities Act is in effect with
respect to the Shares and all state securities laws have been complied with or
unless the Company shall have received an opinion of counsel, satisfactory to
the Company, to the effect that such registration is not required, and the
Investor agrees that certificates representing the Shares issued to it pursuant
hereto may bear the following legend:

                                      -4-
<PAGE>

          THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR
          INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
          1933, AS AMENDED (THE "SECURITIES ACT") OR THE SECURITIES LAWS OF ANY
          STATE. NEITHER THE SHARES NOR ANY INTEREST OR PARTICIPATION IN THE
          SHARES MAY BE SOLD, ASSIGNED, PLEDGED, HYPOTHECATED, ENCUMBERED OR IN
          ANY OTHER MANNER TRANSFERRED OR DISPOSED OF IN THE ABSENCE OF AN
          EFFECTIVE REGISTRATION STATEMENT FOR SUCH SHARES UNDER THE SECURITIES
          ACT, UNLESS, IN THE OPINION (WHICH SHALL BE IN FORM AND SUBSTANCE
          SATISFACTORY TO THE CORPORATION) OF COUNSEL SATISFACTORY TO THE
          CORPORATION, SUCH REGISTRATION IS NOT REQUIRED.

          (b) The Investor agrees not to disclose to third parties any
confidential information concerning the Company which is furnished to such
Investor by the Company except as required by law, legal process or its
fiduciary duty to report financial and business information to its partners or
affiliates. The term "confidential information" does not include information
which (i) was or becomes generally available to the public other than as a
result of a disclosure by such Investor, or (ii) was or becomes available to
such Investor on a non-confidential basis from a source other than the Company,
provided that such source is not bound by a confidentiality agreement with the
Company.

     6. OPINION OF COUNSEL. On or before July 2, 1996, the Company's counsel
will deliver to the Investor an opinion, in form and substance reasonably
satisfactory to the Investor, that the Shares, when sold and delivered in
accordance with this Agreement, will be duly authorized, validly issued and
outstanding, fully paid and non-assessable.

     7.   MISCELLANEOUS.

          (a) AMENDMENTS AND WAIVERS.  This Agreement and any provision hereof
may be changed, waived, discharged or terminated only by an instrument in
writing signed by the party (or any predecessor in interest thereof) against
which enforcement of the same is sought.

          (b) SUCCESSORS AND ASSIGNS. This Agreement will be binding upon and
inure to the benefit of the successors and assigns of the Company and the heirs
and permitted registered assigns and transferees of the Investor.

          (c) TRANSFERABILITY. The Investor may not transfer or assign this
Agreement, or any of the rights or obligations hereunder, unless it is
transferred or assigned to the purchaser of all of the outstanding capital stock
or all or substantially all of the assets, including every right and interest
the Investor may have in the Patent Rights and Know-How, of the Investor. The
Investor further agrees that prior to any transfer of this Agreement, consistent
with this Section, or any transfer of the shares issued hereunder, the Investor
will give written notice to the Company, together with a copy of the opinion of
the Investor's counsel as to the availability of exemption from

                                      -5-
<PAGE>

registration under all applicable securities laws in connection with any such
transfer (which opinion will be reasonably satisfactory to counsel for the
Company).

          (d) LAW GOVERNING.  This Agreement will be governed by, and construed
and enforced in accordance with, the internal laws of the State of Delaware.

          (e) NOTICES. Unless otherwise provided, all notices, requests,
demands and other communications required or permitted under this Agreement will
be in writing and will be deemed to have been duly made and received: (i) upon
personal delivery or confirmed facsimile to the party to be notified; (ii) three
(3) business days after deposit with the United States Post Office, by
registered or certified mail or by first class mail, postage prepaid, addressed
as set forth below; or (iii) one (1) business day after deposit with Federal
Express or another reputable overnight courier (for next business day delivery),
shipping prepaid, addressed as set forth below:

               (i)  If to the Company, then to:

                    GenVec, Inc.
                    12111 Parklawn Drive
                    Rockville, MD 20852

                    ATTN:  Chief Financial Officer

                    with a copy to:

                    Attn: Vice President -- Business Development

              (ii) If to the Investor, then to:

                    Scios Inc.
                    2450 Bayshore Parkway
                    Mountain View, CA 94043

                    ATTN:  General Counsel

                    with a copy to:

                    ATTN:  Vice President -- Business Development

Either party may change the address to which communications are to be sent by
giving five (5) business days' advance notice of such change of address to the
other party in conformity with the provisions of this Section.

          (f) HEADINGS. The headings in this Agreement are for purposes of
reference only and will not affect the meaning or construction or any of the
provisions hereof.

                                      -6-
<PAGE>

          (g) EXECUTION; COUNTERPARTS.  This Agreement may be executed in any
number of counterparts, each of which will be deemed to be an original as
against any party whose signature appears on such counterpart, and all of which
will together constitute one and the same instrument. This Agreement will become
binding when one or more counterparts of this Agreement, individually or taken
together, bear the signatures of all of the parties to this Agreement.

     IN WITNESS WHEREOF, the parties have executed this Class D Preferred Stock
Purchase Agreement as of the date first above written.

                              SCIOS INC.

                              By:
                                    -----------------------------------
                                    Name:
                                    Title:

                              GENVEC, INC.

                              By:
                                    -----------------------------------
                                    Thomas W. D'Alonzo
                                    President

                                      -7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}]]